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TGSWDI MOUSE MODEL OF ALZHEIMER’S DISEASE 
 
Anna Kruyer, Ph.D. 
The Rockefeller University 2015 
 
Numerous epidemiological studies link vascular disorders, such as hypertension, 
diabetes and stroke, with Alzheimer’s disease. Hypertension, specifically, is an 
important modifiable risk factor for late onset Alzheimer’s disease. Despite the 
abundance of clinical data connecting these conditions, animal studies investigating 
the connection between the two are lacking.  
 
To examine the link between midlife hypertension and the onset of Alzheimer’s 
disease later in life, chronic hypertension was induced in the TgSwDI mouse model 
of Alzheimer’s disease in early adulthood using long-term administration of the 
eNOS inhibitor, Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME). L-NAME 
treatment accelerated cognitive deficits, microvascular deposition of the amyloid-
beta peptide, vascular inflammation, blood brain barrier leakage, and pericyte loss in 
these mice.  
 
Though lysosomal markers were increased in hypertensive TgSwDI mice relative to 
all other groups, autophagic structures appeared to be increased in both 
hypertensive TgSwDI mice, as well as hypertensive WT mice. The increased 
 
 
presence of these structures altered cellular morphology at the neurovascular unit 
and compromised the blood brain barrier in hypertensive mice.  
 
Additionally, midlife hypertension induced hippocampal neurodegeneration at an 
early age in TgSwDI mice. Neuronal loss is a defining characteristic of pathology in 
Alzheimer’s disease, but is not replicated in many mouse models of the disease. 
Therefore, this may be a useful research model of Alzheimer’s disease with mixed 
vascular and amyloid pathologies and may display classical features of the disease 
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CHAPTER 1: INTRODUCTION 
Alzheimer’s disease (AD) is the most common form of dementia and there is no 
universal cause, prevention or treatment to delay or stop its progression. Familial 
forms of the disease often involve mutations in genes that result in overproduction of 
the amyloid-beta peptide (Aβ)1, although this is not the cause of the disease in all 
cases. Such mutations affect the expression of the amyloid precursor protein (APP), 
which produces Aβ when cleaved. Mutations affecting production or function of 
presenilin-1 or 2 (PS-1 or -2), which function as part of the gamma-secretase 
intramembrane protease complex, can also result in production of the cleaved 
peptide2. These mutations result in early onset Alzheimer’s disease (EOAD), with 
symptoms arising before the age of 65. Late onset AD (LOAD) often occurs without 
the contribution of known genetic risk factors, but results in symptoms similar to 
those of EOAD, including short term memory loss, confusion, irritability, mood 
swings and eventually long term memory loss3, 4. Individuals with AD exhibit 
deposition of Aβ as plaques in the brain as well as intraneuronal tangles of a highly 
soluble microtubule-associated protein known as tau5. Gradually the neuronal loss 
that characterizes this disease affects other bodily functions and results in death.  
 
Cerebral Amyloid Angiopathy  
Cerebral amyloid angiopathy (CAA), the deposition of Aβ along vessel walls in the 
central nervous system (CNS), is a common feature of AD present in up to 94% of 
AD patients6. The presence of Aβ in vessel walls in the brain has been proposed to 
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result from increased Aβ production of the brains in mouse models of the disease, 
as in humans with EOAD. However, in humans with LOAD, abnormal clearance of 
the peptide is often thought to be the cause7. Aβ can be endocytosed by astrocytes 
and microglia, support cells which function in clearing cell debris and pathogens in 
the CNS8, 9. These cells, as well as neurons, express enzymes, such as neprilysin 
and insulin-degrading enzyme, that allow Aβ to be degraded10. Specific clearance 
across the blood brain barrier (BBB) through molecules like LRP-1 as well as 
shuttling of Aβ-containing interstitial fluid along perivascular spaces have been 
shown to function in Aβ removal from the brain11. Abnormalities in these removal 
pathways may lead to increased CAA abundance in AD patients. 
 
CAA has also been linked to the presence of brain microhemorrhage and even 
increased risk of hemorrhagic stroke12, 13. Though it is difficult to study the effects of 
CAA independent from symptoms of severe AD, as the two are often comorbid, 
some studies suggest a link between CAA and cognitive decline6, 14. While some 
have proposed that CAA specifically contributes to cognitive decline in AD, others 
support the view that CAA simply aggravates the cognitive decline already present 
due to AD15. 
 
Cerebrovascular Dysfunction in Alzheimer’s Disease 
More than 30% of AD cases exhibit cerebrovascular pathology in addition to the 
CAA, microvascular degeneration, and periventricular white matter lesions (WMLs) 
evident in almost all AD cases16. In fact, alterations in every cellular component of 
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the neurovascular unit (NVU), the tightly regulated network of cells involved in the 
coupling of neuronal energy demands to modulation of blood flow (Figure 1.1), have 
been observed in AD patients. Under normal conditions, endothelial cell tight 
junctions form the basis of the BBB (Figure 1.2), while pericytes regulate BBB 
formation and maintenance, vascular architecture, and capillary flow17, 18. In larger 
blood vessels, smooth muscle cell pulsation drives blood flow19. In AD, endothelial 
cells and pericytes degenerate in brain capillaries and smooth muscle cells are lost 
in larger arteries, leading to detrimental effects on neuronal perfusion and function18, 
20-24. Astrocyte endfeet, which ensheath brain capillaries (Figures 1.1, 1.2), help 
regulate capillary blood flow, and maintain the extracellular milieu, are swollen in the 
presence of CAA21, 22. The direct cause of these cellular abnormalities has not been 
determined, though Aβ is toxic to neurons and other cell types in vitro25. Additionally, 
the presence of Aβ amongst the cells of the NVU could interfere with signaling 
between cell types, alter cellular health and function, and contribute to endothelial 
cell degeneration resulting in reduced flow-mediated dilation, an indicator of vessel 
reactivity, also observed in AD brains26. Thus, CAA may contribute to the reduced 
neurovascular coupling reported in multiple AD mouse lines26-29. Furthermore, the 
frequent co-incidence of stroke and AD suggests that the cerebrovascular changes 







Figure 1.1. Structure and function of the NVU. The NVU is the tightly regulated 
network of cells involved in the coupling of neuronal energy demands to modulation 
of blood flow. Endothelial cell (brown) tight junctions form the basis of the BBB and 
keep blood components in the lumen (gray) from entering into the brain (light pink). 
The basement membrane (yellow), a protein matrix composed of collagen, fibrillin, 
laminin, integrins, entactins and dystroglycans, surrounds the endothelial cell layer. 
Sandwiched within the basement membrane are pericytes (blue), which participate 
in BBB formation and maintenance and in the recruitment of capillary flow. 
Surrounding astrocytes (red) extend endfoot processes that serve as the outermost 
layer of the capillary and help regulate capillary flow, maintain the extracellular milieu 





Figure 1.2. Ultrastructure of a normal brain microvessel. (A) A schematic of a 
normal WT capillary in cross-section (B) highlights important morphological features 
of the NVU. The endothelial cell (blue) serves as the first cell layer that separates 
brain tissue from blood components. The endothelial cell tight junction is composed 
of two closely associated areas of membrane that join directly due to the interaction 
of transmembrane proteins. Tight junctions make the endothelial cell layer virtually 
impermeable to fluid under normal circumstances and prevent blood components 
within the vessel lumen (L) from entering the brain. A layer of basement membrane 
(gray), a protein matrix that allows capillary cells to adhere to one another, 
surrounds the endothelial cell. The pericyte (green) is sandwiched within the 
basement membrane layer. The astrocyte endfoot (peach) is a cellular process that 
ensheathes the capillary, providing support for NVU cells as well as aiding in 
regulation of capillary flow (scale bar = 1 µm). 
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Cardiovascular Disease and Alzheimer’s disease 
Clinical evidence suggests that cardiovascular risk factors including atherosclerosis, 
atrial fibrillation, heart disease, diabetes, and hypertension are linked to AD onset16. 
In non-AD individuals, hypertension induces pathological changes in the brain such 
as impaired cerebral autoregulation, vascular remodeling, cerebral microbleeds, 
WMLs, lacunar infarcts, and cerebral atrophy31-34. Though midlife hypertension is a 
significant risk factor for AD and treatment alleviates this risk32, 33, dramatic reduction 
in blood pressure (BP) often occurs at later stages of AD, after which point 
antihypertensive use is deleterious to cognitive function34, 35. It is possible that 
elevated BP during midlife compromises vascular integrity and leads to cellular, 
basement membrane, and/or BBB damage. However, after onset of AD symptoms, 
low BP may aggravate brain hypoperfusion already present in AD due to other types 
of vascular damage. 
 
Given the vasoactive properties of Aβ36, it is unclear whether midlife hypertension is 
an early symptom of the vascular pathology present in AD or if it contributes to the 
onset of the disease, though there is evidence to support both views. Surgically 
induced hypertension in wild type (WT) mice is sufficient to induce subtle increases 
in cerebral Aβ deposition after 10 weeks37. This Aβ deposition has been shown to 
result from upregulation of the receptor for advanced-glycation end products (RAGE) 
at the NVU, which allows transport of Aβ from the circulation into the brain38. 
Alternatively, Aβ has been shown to be vasoactive and may itself contribute to the 
onset of hypertension39. 
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Autophagy in Alzheimer’s Disease 
Macroautophagy, referred to herein as “autophagy”, is the process by which 
unnecessary or dysfunctional cytoplasmic components are degraded by 
lysosomes40. Under normal conditions, autophagy is a very efficient process and 
autophagosomes, containing cellular debris, or amphisomes, containing 
endocytosed extracellular material, are rapidly cleared by fusion with lysosomes41 
(Figure 1.3). For this reason, active autophagy is scarcely observed in tissues like 
the brain42. Given that AD is a disease of excessive protein accumulation, it is not 
surprising that autophagy has been found to be increased in brains of AD patients43. 
Autophagy plays a central role in the pathophysiology of AD and dysfunction of this 
process is deleterious to neuronal function. Interestingly, mice overexpressing 
human APP and also null for the autophagy-related gene 7 (Atg7) exhibit reduced 
parenchymal Aβ deposition due to inhibited Aβ secretion from cells44. However, this 
reduction in Aβ deposition corresponds with increased intracellular Aβ-load and 








Figure 1.3. Degradation of intracellular and extracellular components by 
lysosomes. Autophagy is the basic catabolic mechanism for degradation of 
unnecessary or dysfunctional cellular components. Target cytoplasmic constituents 
are isolated from the cytoplasm by a double-membraned vesicle known as the 
autophagosome. An autolysosome, or autophagic vacuole, is formed when the 
autophagosome fuses its external membrane with the membrane of the lysosome. 
Endosomes, containing extracellular components imported for degradation, mature 
to form multivesicular bodies (MVBs) that fuse either directly with the lysosome or 
with a late autophagosome to form an amphisome. After lysosome fusion, 
degradation of autophagosome, endosome or amphisome components are 
mediated by acidic lysosomal hydrolases. Permeases on autolysosomal membranes 
allow diffusion of degraded components back into the cytoplasm.  
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Though changes in lysosomal function occur with age41, it has been proposed that 
Aβ is itself the substrate of dysfunctional autophagy in AD and is also the cause45. 
Autophagic vacuoles (AV), intracellular membrane-bound components bound for 
fusion with lysosomes, are abundant in AD neurons46, leading some to propose that 
early autophagic processes are functional in AD, but fusion with lysosomes and/or 
post-autophagic clearance mechanisms are impaired42. One proposed barrier to 
autophagic efficiency in AD is that autophagosomes form in synapses where 
misfolded tau aggregates. Autophagosomes must undergo retrograde transport to 
the cell soma, where lysosomes are most abundant, for degradation. When neurites 
become damaged due to disruption of tau microfilaments, this retrograde transport is 
impaired and AVs accumulate in swollen dystrophic and degenerating neurites47. 
Thus the necessity for increased lysosome activity in AD paired with defective 
lysosomal clearance mechanisms create conditions favorable for protein 
aggregation and cellular damage.  
 
Alzheimer’s Disease Mouse Models 
Mouse models have been instrumental to the progress made in understanding and 
attempting to treat AD. The identification of APP mutations in families with EOAD led 
to the understanding that misprocessing of this protein was linked to disease onset. 
Homologous recombination was ultimately used to insert the human APP gene, 
containing known AD-causing mutations identified in EOAD families, into the mouse 
genome, leading to the development of numerous mouse models and a more 
aggressive study of AD in vivo. The first mouse model available for widespread use 
 10 
was the PDAPP model, which expressed transgenic human APP carrying the 
Indiana mutation (V717F) under the platelet-derived growth factor (PDGF) promoter, 
leading to expression of transgenic APP in neurons48. Researchers found that 40 
copies of transgenic APP had integrated into the mouse genome, resulting in an 18-
fold elevation of APP RNA and a 10-fold elevation of human APP protein expression 
compared to mouse APP49.  Similar corresponding changes were observed when 
levels of Aβ peptide were quantified. Furthermore, these mice exhibited Aβ plaque 
deposition, neuroinflammation, learning deficits and synapse loss in an age-
dependent manner, all consistent with pathological changes observed in human AD 
patients. 
 
The Arctic, Australian, Austrian, Belgian, Dutch, English, Flemish, Florida, French, 
German, Indiana, Iowa, Iranian, Leuven, London, Osaka, Swedish, Taiwanese and 
Tottori mutations are all named after geographic locations of families carrying 
specific mutations in APP that result in EOAD. Different combinations of these and 
PS-1 and -2 mutations have been inserted into the genomes of mice in order to 
generate models with different pathological characteristics comparable to what is 
observed in humans with both EOAD and LOAD.  
 
TgSwDI Mouse Model 
Many AD mouse models have been generated since the introduction of the PDAPP 
mouse model to research, each presenting with different features of AD that are of 
interest to researchers. The TgSwDI mouse model is unique among other AD mouse 
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models, since it represents the first model of CAA. Other AD mouse models exhibit 
CAA, especially during later stages of pathological progression, but TgSwDI mice 
display dramatically increased microvascular Aβ deposits relative to parenchymal 
deposits in the brain 50. This mouse line carries a human APP transgene containing 
three sets of EOAD mutations driven by the thymus cell antigen 1, theta (Thy1) 
promoter that leads to predominant expression of transgenic APP in neurons and 
some glia in the striatum and hippocampus. The Swedish mutation (Sw) results in 
two adjacent amino acid substitutions (K670M/N671L) and sits at the β-secretase 
cleavage site of APP, likely leading to increased cleavage of APP and thus 
increased Aβ production50 (Figure 1.4). The Dutch (D) and Iowa (I) mutations 
(E693Q and D694N, respectively) refer to adjacent amino acid substitutions that 
likely increase deposition of Aβ along vessels rather than within in the brain 
parenchyma (Figure 1.4). This mouse model exhibits dramatically increased 
capillary CAA in parts of the hippocampus and the thalamus, but decreased plaque 
deposition relative to other models. Additionally, the CAA in this mouse model yields 
neuroinflammation and cognitive decline consistent with AD.  
 
The TgSwDI mouse model was generated by the Van Nostrand group at Stony 
Brook University and its pathology has been well characterized by members of the 
group50-52. They have observed Aβ deposition in the subiculum, hippocampus and 
cortex of these mice at 3 months-of-age and widespread deposition in the forebrain 
by 12 months-of-age. Researchers from this group report that early microvascular 
Aβ deposits are largely Aβ40 in composition. In fact Aβ40 is ten times more 
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abundant in the brains of these mice than Aβ42. The length of the Aβ peptide, 
typically 37-43 residues, is determined by the gamma secretase protein complex, 
which cleaves Aβ at its C-terminal end53. Aβ40 is produced more readily than Aβ42 
and is abundant in CAA; Aβ42 has been shown to be more fibrillogenic and more 
toxic than Aβ4054, 55. Microvascular Aβ accumulation in TgSwDI mice is mostly 
fibrillar and Aβ is 13-fold more abundant near microvessels than in the parenchyma. 
In fact, 50% of forebrain vessels exhibit CAA. This group cites both increased 
production as well as decreased clearance of mutant Aβ as the cause for increased 



















Figure 1.4. APP mutations expressed by the transgenic TgSwDI mouse line. 
The TgSwDI mouse model of AD carries a human APP transgene, driven by the 
neuronal Thy1 promoter, with mutations all near or within the region cleaved to form 
the Aβ peptide (orange rectangle). All of the mutations in the inserted transgene 
were found to be expressed by different families with EOAD. The Swedish mutation 
refers to two adjacent amino acid substitutions, K670M and N671L, which lie at the 
β-secretase cleavage site of APP. These mutations likely lead to increased 
production of the Aβ peptide. The Dutch and Iowa mutations are adjacent 
substitutions (E693Q and D694N, respectively) that increase the likelihood that the 
resulting Aβ peptide will be deposited along vessels in the brain rather than in the 
brain parenchyma.  
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Given the largely vascular Aβ pathology in the TgSwDI mouse model and my 
interest in studying the link between vascular dysfunction and AD onset, I examined 
TgSwDI mice for potential effects of CAA on AD progression. I also induced chronic 
hypertension in TgSwDI mice and examined behavioral, cellular, and ultrastructural 
















CHAPTER 2: MATERIALS AND METHODS 
Animal Use 
TgSwDI +/+ and C57Bl6J mice were purchased from The Jackson Laboratory and 
bred in house to generate the mice used for experiments described in Chapter 3. 
TgSwDI +/- and -/- littermates were generated using in vitro fertilization (IVF) at the 
Transgenic Services Laboratory at The Rockefeller University and were used to 
conduct the experiments described in Chapter 6. Both TgSwDI +/+ and +/- animals 
as well as either C57Bl6J or TgSwDI -/- controls were used for experiments 
described in Chapters 4 and 5. For this reason, a Table listing the genotypes of AD 
and WT groups for each set of experiments described herein has been included for 
reference (Table 2.1). Genotypes were determined by PCR on tail samples taken 
before weaning. TgSwDI +/+ or +/- mice were considered AD animals, and C57Bl6J 
or TgSwDI -/- mice were used as WT controls. When described, TgCRND8 +/- and 
Tg6799 +/- were also considered AD and TgCRND8 -/- and Tg6799 -/-, respectively, 
were used as WT controls. All mice were maintained on a 12-hour light/dark cycle 
with food and water provided ad libitum and mice of both sexes were used in 
approximately equal ratios for all experiments, except when otherwise specified 
(Table 2.1). All animal procedures were approved by the Institutional Animal Care 










Table 2.1. AD and WT cohort details by experiment. 






The presence of the TgSwDI transgene was assessed in DNA preparations from tail 
samples of TgSwDI +/- and -/- using primers against the transgene and an internal 
control gene (oIMR5260, 0IMR5261, oIMR1544, oIMR3580; The Jackson 
Laboratory) and the following polymerase chain reaction (PCR) conditions: 3 
minutes at 94°C; 30 seconds at 94°C, 1 minute at 52°C, and 1 minute at 72°C, 
repeated for 35 consecutive cycles; 2 minutes at 72°C.  
 
Statistics 
All numerical data are presented as mean ± standard error of the mean. Statistical 
significance of data collected over time (BP, Barnes maze performance curves) was 
determined using a two-way ANOVA with a Bonferroni post-hoc correction. In all 
other cases, statistical significance was determined using a 2-tailed Student’s t-test 




Mice were allowed to freely explore an open-armed Y-shaped maze for 5 minutes in 
low lighting (50 lux). The order of arm entry was scored and alternation was 
determined by dividing the number of arm entry triads (all three arms visited 
subsequently) by the total number of arm visits minus 256. Percent alternation was 
compared between groups. For this and all subsequent behavior tests described, 
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scoring was conducted by an experimenter who was blind to the genotype and to the 
treatment and age (when relevant) of all animals.  
 
Barnes Maze 
The Barnes maze apparatus (TAP Plastics) consisted of a white circular platform 92 
cm in diameter with 20 equally spaced holes, each 5 cm in diameter and 7.5 cm 
apart. Of these holes, 19 were blocked with black plastic and 1 (target hole) was 
routed to a black escape box that was secured below the surface of the table.  Distal 
visual cues consisting of black and white geometric shapes were placed throughout 
the testing room, and ambient lighting was kept high (1500 lux) to motivate animals 
to find and enter the escape box.  During training, mice were allowed to search the 
maze for the target hole for 2 minutes, after which time they were guided to the 
target hole. Training consisted of 1 trial per day for each mouse for 4 consecutive 
days. On the fifth day, a probe trial was carried out to assess spatial memory of the 
mice (24-hr probe trial) 57. The target hole was blocked off with black plastic, and the 
mice were allowed to explore the maze for 90 seconds while their behavior was 
recorded. An extended probe trial was held five days later (5-d probe trial). All trials 
were recorded and scored for latency to find the target hole (first nose poke) as well 
as latency to enter the target hole using Ethovision software (Noldus). Velocity, 
distanced traveled, and number of entries into the area around the target hole were 
determined and compared between groups.  
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Contextual Fear Conditioning 
Fear conditioning experiments were run in a conditioning chamber (MedAssociates) 
equipped with a light and an overhead video camera and all trials were recorded for 
subsequent scoring. On the first day of the test, mice were placed in a conditioning 
chamber that had been cleaned with 70% ethanol and were allowed to habituate to 
the chamber for 2 minutes. Animal behavior during these first 2 minutes was used to 
assess baseline freezing behavior. Mice then received 2 foot shocks (0.7 mA for 2 
seconds each), one minute apart. Mice were removed from the chamber 30 seconds 
after the last foot shock. After 24 hours, each mouse was placed into the same 
chamber in which it received foot shocks the previous day and allowed to explore 
the chamber for 5 minutes while its movements were recorded. Freezing behavior 
for all trials was scored in 5-second bins and was taken to indicate a mouse’s 
memory of the foot shocks from the previous day58. 
 
Porsolt Swim Test 
Each mouse was placed in a 4-L transparent beaker filled to 80% capacity with room 
temperature water. The final water level was 5 cm below the mouth of the beaker, so 
mice were not able to attempt escape. Mobility of each mouse in the water was 
observed for 6 minutes and all trials were video recorded for later analysis59. Animal 
movement was scored manually every 5 seconds and immobility was defined as 
lack of movement, except for that which was required to keep the animal afloat. The 




Mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and 
perfused with 5 mL 0.9% saline followed by 15-30 mL 4% paraformaldehyde (PFA) 
according to body weight. Brains were post-fixed overnight in 4% PFA and 
cryoprotected for 24 hours in 30% sucrose in 0.1 M phosphate buffer at 4°C. Brains 
were then frozen on powdered dry ice and sliced into 30-micron coronal sections 
using a microtome. Sections were collected into freezing medium (30% glycerol, 
30% ethylene glycol, 40% 0.1 M phosphate buffer) and stored at -20°C until use. 
Hippocampus-containing free-floating brain sections were mounted on glass slides 
using a gelatin-based mounting medium and dried overnight at room temperature.  
 
Slides were rinsed upright in 1X PBS for 5 minutes before undergoing antigen 
retrieval. Antigen retrieval conditions were determined for each antibody (Table 2.2) 
and included no treatment, incubation in Proteinase K (Dako) and/or boiling in 
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20 in ddH2O, pH 6.0). 
Slides were rinsed 3 times for 5 minutes each in 1X PBS and blocked in 3% normal 
donkey serum with 0.3% Triton X-100 in 1X PBS for 1 hour at room temperature. 
Antibodies were diluted in blocking buffer at concentrations ranging from 1:100-
1:10,000 and sections were incubated in primary antibody solution for 12-18 hours at 
room temperature and then washed in 1X PBS 3 times for 5 minutes each. Sections 
were incubated in fluorescently-labeled secondary antibody (Alexa Fluor, donkey 
anti-host species, 1:200) for 1-2 hours at room temperature, then washed and 
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covered using ProLong Gold antifade reagent (Life Technologies) and microscope 
cover glass (Fisher).  
 
Sections were visualized using an Axiovert 200 inverted epifluorescence microscope 
or an LSM510 laser scanning confocal microscope (Carl Zeiss, Inc.). All sections 
were imaged at 20x-40x magnification. Exposure time and gain were consistent for 





































Mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and 
perfused with 15-30 mL 0.9% saline according to body weight. After perfusion, 
brains were removed and immediately covered in powdered dry ice. Brains were 
stored at -80°C until slicing into 30-micron coronal sections using a cryostat. Tissue 
sections were thaw-mounted directly onto glass slides and stored at -80°C until use. 
Staining was carried out as in “Fixed Immunohistochemistry”, but with brief fixation 
using 4% PFA or ethanol (Table 2.2) and without antigen retrieval.  
 
Thioflavin S Staining 
Hippocampus-containing fixed free-floating coronal brain sections were mounted 
onto glass slides using a gelatin-based mounting medium and dried overnight at 
room temperature. Slides were rinsed in 1X PBS and immersed in Thioflavin S 
(ThioS) solution (0.02% Thioflavin S dissolved in ddH2O and filtered, Sigma-Aldrich) 
for 30 minutes at room temperature. Slides were then immersed in 70% ethanol for 
15 minutes, washed and covered using ProLong Gold antifade reagent (Life 
Technologies) and microscope cover glass. Z-stacks containing 5 images, each 1 
µm apart, were collected for each hippocampal subregion at 25X magnification using 
an inverted LSM510 laser scanning confocal microscope (Carl Zeiss, Inc.). Exposure 
time and gain were consistent between all sections from all animals. 
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Evans Blue Extravasation Assay 
A solution of 2% Evans blue (Sigma-Aldrich) in 0.9% saline was injected (10 mL/kg 
body weight) intraperitoneally (IP) into each mouse. 24 hours after injection, mice 
were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and 
perfused transcardially with 0.9% saline to remove the intravascular dye. Brains 
were frozen immediately on powdered dry ice and kept at -80C until sectioning. 
Brains were sectioned coronally at 30 microns using a cryostat and Evans blue 
extravasation was assessed directly by analysis of fluorescence in hippocampal 
subregions at 20x-40x magnification. 
 
L-NAME-Induced Hypertension 
Mice were weighed and divided into cages according to treatment type. Water 
consumption per cage was quantified over a 7-day period and Nω-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME, Sigma-Aldrich) was diluted into drinking water 
so that each mouse consumed approximately 100 mg/kg body weight per day. 
Treatment was initiated at 3-4 months-of-age and continued for 3 or 6 months. 
 
Angiotensin-II and L-NAME-Induced Hypertension 
Mice were anesthetized by IP injection of 2.5% tribromoethanol (500 mg/kg body 
weight) and atropine (0.04 mg/kg body weight) and osmotic infusion pumps (Alzet) 
were implanted subcutaneously at the scruff of the neck to deliver 1 µg/kg body 
weight per minute angiotensin II (Ang-II, Sigma-Aldrich) dissolved in sterile 0.9% 
saline. Surgical incisions were stitched closed using 6-0 silk sutures (Harvard 
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Apparatus). Following surgery, mice were injected IP with buprenorphine HCl (0.03 
mg/kg body weight) and 500 µL sterile 0.9% saline and allowed to recover on a 
heating pad. Additionally, L-NAME was delivered as described in “L-NAME-induced 
Hypertension”. 
Tail Cuff Plethysmography 
BP was measured one week prior to and every week during Ang-II and/or L-NAME 
treatment by tail cuff plethysmography according to the manufacturer’s instructions 
(Kent Scientific). Mice were placed in a restrainer and rested on top of a heating pad 
to keep body temperature around 37°C. Three BP readings were obtained and 
averaged for each animal.   
Stereology 
Images of hippocampal subregions (Figure 2.1), the dentate gyrus (DG), the dorsal 
subiculum (DS), cornu ammonis 1 (CA1) and cornu ammonis 3 (CA3), from 
immunostained tissue were quantified using NIH Image J software. Hippocampus 
subregions were identified and outlined.  Stained images were split into their 
component red, green and blue color channels, and the channel containing signal 
was selected for further processing.  Images were thresholded manually to yield 
intensity in the areas containing apparent signal but not in background.  Signal value 
was normalized to the size of the area from which it was extracted. For “vessel 
coverage” quantifications, stretches containing pixels of both the marker of interest 
and a vascular marker were selected using the line selection tool, added and 
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normalized to the size of the region quantified. Signal intensity, item number and 
pixel length was analyzed for each subregion and then compared between groups. 
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Figure 2.1. Anatomical map of hippocampal subregions. The hippocampus 
coordinates memory consolidation and spatial navigation and is one of the first 
regions in the brain to suffer damage in humans with AD and in the TgSwDI mouse 
model of AD. Hippocampal subregions are depicted here in a schematic of a coronal 
section through the hippocampus. The DG (green) receives excitatory inputs from 
the entorhinal cortex (not shown) and projects to pyramidal cells in the CA3 (light 
blue) via the mossy fiber tract. The DG is thought to be involved in pattern 
separation, as it converts similar inputs to substantially different outputs. 
Behaviorally, it contributes to the formation of new episodic memories and 
spontaneous exploration of novel environments. Additionally, the neurogenesis that 
happens in the DG contributes to spatial memory formation. Schaffer collaterals 
connect the CA3 to the CA1 (dark blue). The CA1 has been proposed to perform 
match-mismatch roles in the hippocampus, comparing memory retrieval with 
sensory input. CA1 cells synapse in the subiculum (dorsal subiculum, red) for relay 
out of the hippocampus. The subiculum is implicated in working memory and 
processing of spatial relationships, as well as the spread of Aβ to other hippocampal 




Mice were heavily anesthetized by IP injection of 2.5% tribromoethanol and were 
perfused with 0.9% saline followed by 15-30 mL 4% PFA according to body weight 
at slow speed. Brains were removed, immersed in 4% PFA, and sliced into 50-µm 
sections using a Leica VT 1000S vibrating blade microtome. The dorsal subiculum 
was removed and frozen in liquid nitrogen under high pressure using a Leica EM 
PACT2. Freeze substitution was performed using a Leica AFS2 automatic freeze 
substitution unit60. Tissue was sectioned at 90 nm onto carbon-coated copper mesh 
grids. After drying, grids were rinsed in 20 mM HEPES, pH 7.5, blocked with 3% 
bovine serum albumin (BSA) and 0.1% saponin in 20 mM HEPES, pH 7.5 for 2 
hours at room temperature and incubated in primary antibody (1:900-1:32,000) at 
4°C overnight (Biosource). Grids were then washed, incubated in blocking solution 
for 5 minutes, and incubated in 12-nm gold anti-host species secondary antibody 
(Jackson ImmunoResearch) in a solution containing 0.5% BSA, 0.1% saponin, and 
20 mM HEPES, pH 7.5, for 1 hour at room temperature. After washing and fixing in 
2.5% glutaraldehyde for 3 minutes, tissue sections were imaged using a JEOL 
100CX transmission electron microscope at 80 kV. All post-perfusion steps were 
conducted at The Rockefeller University Electron Microscopy Resource Center 
(EMRC). 
Transmission Electron Microscopy 
Mice were heavily anesthetized by IP injection of 2.5% tribromoethanol and were 
perfused with 0.9% saline followed by 15-30 mL 4% PFA according to body weight 
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at a slow speed. Brains were removed and sliced using a brain matrix into 1-mm 
thick coronal sections. Sections were then immersed in 2.5% glutaraldehyde in 0.1 
M sodium cacodylate buffer with 2 mM CaCl2 at 4°C for 24 hours. Sections were 
immersed in 0.1 M sodium cacodylate buffer at 4°C for 24 hours and the dorsal 
subiculum was isolated. Tissue was post-fixed with 1% osmium tetroxide and 0.5-
1.5% potassium ferrocyanide in 0.1 M sodium cacodylate buffer for 1 hour on ice. 
Tissue was washed once in 0.1 M sodium cacodylate buffer and twice in ddH2O and 
stained in 1% uranyl acetate for 30 minutes at room temperature. Tissue was then 
quickly washed in water and dehydrated in increasing concentrations of ethanol 
(70%, 80%, 95%, 100%, 100%, 100%), followed by propylene oxide for 10 minutes 
each at room temperature. Propylene oxide was replaced with two exchanges of 
EMbed812 resin and tissue was placed under vacuum for 24 hours at room 
temperature.  The resin was exchanged three more times over the following 24 
hours and kept under vacuum before samples were cured in resin for 48 hours at 
60°C. The tissue was sliced at 60-80 nm using a Leica Ultracut E and visualized 
using a JEOL 100CX transmission electron microscope at 80 kV. All post-perfusion 
steps were conducted at the Rockefeller University EMRC.  
3View 
Mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and 
perfused with 5 mL 0.9% saline followed by 15-30 mL 4% PFA according to body 
weight at slow speed. Brains were removed, immersed in 4% PFA, sliced into 100-
µm sections using a Leica VT 1000S vibrating blade microtome and the dorsal 
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subiculum was removed and immersed in 4% PFA and 2.5% glutaraldehyde in 0.1 
M sodium cacodylate buffer with 2 mM CaCl2 overnight. The tissue was washed and 
incubated in 1.5% potassium ferrocyanide, 2% osmium tetroxide in 0.1 M sodium 
cacodylate buffer with 2 mM CaCl2 for 1 hour on ice. Tissue was then washed with 
room temperature ddH2O and incubated in filtered 0.1% thiocarbohydrazide solution 
in ddH2O for 20 minutes. After rinsing, the tissue was re-exposed to 2% osmium 
tetroxide for 30 minutes, washed and incubated in aqueous 1% uranyl acetate for 
12-18 hours. The tissue was stained in aqueous 20 mM lead nitrate and 30 mM 
aspartic acid, pH 5.5, at 60C for 30 minutes. After washing, the tissue was 
dehydrated in increasing concentrations of ethanol (20%, 50%, 75%, 100%, 100%, 
100%) in a Pelco Biowave at 10C and 150 watts for 40 seconds each, then placed in 
ice-cold acetone for 10 minutes, followed by room temperature acetone for 10 
minutes. Increasing concentrations of durcupan resin in acetone was infiltrated into 
samples using a Pelco Biowave (25%, 50%, 75%, 100%, 100%) and left to infiltrate 
under vacuum overnight. Samples were embedded between sheets of aclar and 
cured at 60°C for 48 hours. After mounting, blocks were trimmed and sputter coated 
for 120 seconds using gold/palladium (Denton). The tissue surface was imaged 
every 50 nm for 25 µm using a MERLIN scanning electron microscope (Carl Zeiss, 
Inc.) and processed using Gatan 3View System software. 
Western Blotting 
Fresh hippocampi or dorsal subiculum samples were dissected on ice and 
homogenized in lysis buffer (25 mM Tris-HCl, pH 7.6; 150 mM NaCl, 1% NP-40, 1% 
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sodium deoxycholate, 0.1% SDS) with protease and phosphatase inhibitors added 
(Sigma-Aldrich, Roche) and sonicated on ice. After large cellular debris was 
removed from samples by centrifugation, protein concentration was determined by 
spectrophotometry using a bicinchoninic acid (BCA) kit (Thermo Scientific) according 
to the manufacturer’s instructions. Loading dye with β-mercaptoethanol was added 
to the samples, which were then boiled for 5 minutes at 100C. 20-30 µg of protein 
were loaded per lane and samples were run on a denaturing 8% Tris-Glycine gel, 
transferred to a nitrocellulose membrane and blocked in a 5% milk and 3% BSA 
solution dissolved in Tris-buffered saline with 0.5% Tween 20. Blots were probed 
with antibodies (1:1000-1:2000) in blocking buffer at 4°C overnight and washed. 
Blots were then incubated with the appropriate HRP-labeled secondary antibody 
(1:5000-1:10,000) in blocking buffer, washed again, incubated in chemiluminescent 
reagent (PerkinElmer) and exposed to film. Band intensity was quantified using NIH 
ImageJ software and normalized to actin from the same blot. 
Hypoxyprobe Detection 
A solution of 60 mg/kg body weight pimonidazole HCl (dissolved in sterile 0.9% 
saline, Hypoxyprobe) was injected IP into each mouse. 60 minutes after injection, 
the mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and 
perfused transcardially with 15-30 mL 0.9% saline according to body weight. Brains 
were removed and frozen immediately on powdered dry ice and kept at -80°C until 
sectioning. Brains were sectioned coronally at 30 microns onto glass slides using a 
cryostat and stored at -80°C until use. Slides were then incubated in FITC-MAb1 
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according to the manufacturer’s instructions. Hippocampal subregions within stained 
sections were imaged at 20-40x magnification. 
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CHAPTER 3: CHARACTERIZATION OF ALZHEIMER’S NEUROPATHOLOGY IN 
THE TGSWDI MOUSE MODEL 
Cognitive Decline  
Cognitive decline was examined in TgSwDI mice by a variety of behavioral tests. 
Given that previous publications reported cognitive decline in TgSwDI mice at 3 
months-of-age52, but had not yet tested younger mice (W. Van Nostrand, personal 
communication), TgSwDI mice were tested for learning and memory impairments at 
2, 3 and 6 months-of-age. Though 2-, 3- and 6-month-old TgSwDI mice exhibited no 
differences in spontaneous alternation using the Y-maze test or expression of 
learned fear after fear conditioning, 6-month-old TgSwDI mice did exhibit a reduced 
preference for the target hole (Figure 3.1A) during the 5-d probe trial in the Barnes 
maze, a test of spatial learning and memory57, when compared to age-matched WTs 
(Figure 3.1B). Thus the earliest detectable indication of cognitive decline in this 
colony of TgSwDI mice occurred at 6 months-of-age. 
35 
Figure 3.1. TgSwDI mice exhibit cognitive deficits at 6 months-of-age. (A) The 
Barnes maze tests spatial learning and memory. Mice were trained to find the 
location of a target hole (red) that led to a hidden escape box (blue) based on visual 
cues around the maze and were tested for their learned preference for the area near 
the target hole after training. (B) At 6 months-of-age, TgSwDI mice exhibited no 
preference for the target hole during the 5-d probe trial, compared to WT mice 
(p<0.05). TgSwDI also exhibited reduced preference for the hole adjacent to the 




Compared to WT mice and 2-month-old TgSwDI mice, which exhibited no Aβ 
deposition in the brain by ThioS staining, TgSwDI mice exhibited more Aβ in the 
hippocampus starting at 3 months-of-age (Figure 3.2). TgSwDI mice exhibited a 
small amount of Aβ in the DS and DG regions of the hippocampus at 3 months-of-
age, though the deposition appeared in small plaque-like patches (Figure 3.2B). By 
6 months-of-age, ThioS staining revealed abundant CAA and decreased presence of 
parenchymal plaques relative to earlier time points (Figure 3.2C vs. 3.2A,B). 
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Figure 3.2. Pattern of Aβ deposition over time in TgSwDI mice. Deposition of Aβ 
in the DS was examined in 2- (A), 3- (B), and 6-month-old (C) TgSwDI mice by 
ThioS staining (green). Anti-collagen IV co-staining (red) was used to identify 
capillaries. At 2 months-of-age, TgSwDI mice exhibited little-to-no ThioS-positive 
signal in the DS (A), whereas small diffuse plaques were observed by 3 months-of-
age (B). At 6 months-of-age, parenchymal plaque-load was reduced and Aβ was 
abundant along capillaries in the brain (C; scale bar = 50 µm).  
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Gliosis  
Microglia activation in TgSwDI mice was determined by abundance of microglia 
compared to WT (Figure 3.3). Microglia were stained using a fluorescently-labeled 
tomato isolectin, a sugar-binding glycoprotein with specific affinity for poly-N-acetyl 
lactosamine residues present on the surface membranes of microglia and 
endothelial cells61. Positive signal was determined to be microglial rather than 
endothelial based on morphology of stained cells. TgSwDI mice (Figure 3.3D-F) 
exhibited more microglia-like staining at 2, 3 and 6 months-of-age in the DG and DS 
compared to WT mice that exhibited no observable microgliosis at these ages 
(Figure 3.3A-C). Importantly, this result demonstrates that microgliosis preceded 
both Aβ deposition as plaques, which occurred at 3 months-of-age in TgSwDI mice, 
and as CAA, which occurred at 6 months-of-age (Figure 3.2). 
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Figure 3.3. Microgliosis precedes Aβ deposition in TgSwDI mouse brains. 
Fluorescently-labeled tomato isolectin (green) is a sugar-binding glycoprotein with 
specific affinity for sugar residues on microglial and endothelial cell surfaces. 
Stained endothelial cells and microglia are morphologically distinct; capillary 
endothelial cells were present in all images and appeared as thin streaks, while 
microglia appeared as large patches of dense signal. The increased appearance of 
microglia in the DS of 2- (D), 3- (E), and 6-month-old (F) TgSwDI mice compared to 
WT mice of the same ages (A, 2-months; B, 3-months; C, 6-months-old) indicate 
that microglia were activated in TgSwDI brains as early as 2 months-of-age. 
Microgliosis becomes apparent in the DG of TgSwDI mice around 6 months-of-age, 
later than in the DS (F vs. D, scale bar = 100 µm).  
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BBB Integrity 
The Evans blue injection model was used to determine the age at which TgSwDI 
mice first exhibited BBB breakdown (Figure 3.4). When injected IP, the azo dye 
Evans blue (red) enters the blood stream and binds to albumin with high affinity. 
Under normal conditions, the plasma protein albumin (65 kDa) is too big to cross the 
BBB and is removed during perfusion along with the associated Evans blue. In the 
case of a leaky BBB, however, albumin carries Evans blue into the brain 
parenchyma where it can be detected by fluorescence microscopy. After injection, 
Evans blue was detected in the cortex and hippocampus of 3-month-old TgSwDI 
mice (Figure 3.4B), but not in 2-month-old TgSwDI mice (not shown) or WT mice at 
any age examined (up to 12 months; Figure 3.4A). By 12 months-of-age, Evans blue 
leakage in the brains of TgSwDI mice was prominent (Figure 3.4D).  
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Figure 3.4. TgSwDI mice exhibit early BBB breakdown. Evans blue was injected 
into TgSwDI and WT mice of different ages (A-D). 18 hours after injection, mice 
were perfused with saline and their brains removed. Imaging revealed the presence 
of Evans blue in the DS of TgSwDI mice as early as 3 months-of-age (B). Evans 
blue leakage was severe at 6 (C) and 12 months-of-age (D) in TgSwDI  mice 
compared to WT mice at 12 months-of-age (A), where little-to-no signal was 
observed (scale bar = 50 µm). 
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Autophagy 
Lysosomal-associated membrane protein-1 (LAMP-1) was used as an autophagic 
marker since it is present on both lysosomal and endosomal membranes62 (Figure 
3.5).  LAMP-1 is often increased at dysfunctional synapses in AD, as AVs are known 
to build up in dystrophic neurites in the brain46. LAMP-1 signal was evident in the DS 
of TgSwDI mice as early as 3 months-of-age (Figure 3.5B), the earliest age 
examined. By 6 months-of-age, LAMP-1 staining was evident in the DS and DG 
(Figure 3.5C) as well as the thalamus (not shown), suggesting that pathology was 
not only more severe at this age, but also more extensive.  Though LAMP-1 
immunostaining is typically used to indicate synaptic dysfunction in AD mice, it is 
possible that other cell types in the brain were responsible for the observed increase 
in LAMP-1 staining, as no cell type-specific co-stain was used. LAMP-1 signal 
became more diffuse in the DS at 6 months-of-age, possibly coincident with the 
transition from Aβ deposition as plaques to CAA (Figure 3.2). 
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Figure 3.5. TgSwDI mice display evidence of increased autophagy. LAMP-1, a 
protein present on lysosomal and endosomal membranes, was examined in TgSwDI 
and WT brain tissue using an anti-LAMP-1 antibody (A-C). At 6 months-of-age, no 
LAMP-1 was detectable in the hippocampus of WT mice (A). In TgSwDI mice at 3 
months-of-age, LAMP-1 appeared as small clusters in the DS of the hippocampus 
(B). LAMP-1 staining was also present as clumps in the DG and CA1 in TgSwDI 
mice at 6 months-of-age (C). The LAMP-1 signal in the DS at this time point was 
more widespread, though large patches were no longer apparent (scale bar = 100 
µm). 
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Differences in Depressiveness, Anxiety and Locomotion in TgSwDI Mice 
Researchers who generated the TgSwDI mouse line report early cognitive deficits, 
but no changes in balance, locomotion or anxiety52. However, TgSwDI mice from the 
colony I examined exhibited significant differences in defecation, an indication of 
anxiety level in mice, in a number of behavioral tests during testing for onset of 
cognitive decline (Figure 3.6). During Barnes maze testing, TgSwDI mice exhibited 
increased defecation at all ages (Figure 3.6A-C), a finding that was similar during 
fear conditioning (Figure 3.6D).  TgSwDI mice also exhibited increased learned 
helplessness at 3 months-of-age on the Porsolt swim test (Figure 3.6E). Together, 
these findings suggest differences in emotionality in TgSwDI mice compared to WT 
mice, independent of cognitive decline, which was only detectable at 6 months-of-
age (Figure 3.1). 
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Figure 3.6. TgSwDI mice exhibit increased anxiety- and depressive-like 
behaviors. (A-C) During Barnes maze training, TgSwDI mice defecated more than 
age-matched WT control mice at 2 (A), 3 (B) and 6 months-of-age (C; *p<0.05, 
**p<0.01). Defecation is an indication of anxiety in mice and decreased gradually 
over the course of Barnes maze training in most groups. (D) During fear 
conditioning, defecation decreased with age in WT mice, but remained elevated in 
TgSwDI mice at 2, 3 and 6 months-of-age (*p<0.05, **p<0.01). (E) The Porsolt swim 
test is used to examine depressive-like behavior in mice. A reduced latency to 
immobility is known as “learned helplessness”, a behavioral output that is similar to 
some features of depression in humans. TgSwDI exhibited shorter latencies to 
immobility at 3 months-of-age compared to age-matched WT controls (E, *p<0.05). 
This trend persisted at 6 months-of-age (not shown).  
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TgSwDI mice also exhibited reduced mobility in multiple behavioral tests relative to 
WT mice (Figure 3.7). During Y-maze testing, TgSwDI mice were consistently less 
mobile than WTs at 2, 3 and 6 months-of-age (Figure 3.7A). During Barnes maze 
testing, TgSwDI mice exhibited an age-dependent reduction in mobility (Figure 
3.7B). Given these results, it is unclear whether the decreased latency to immobility 
observed in TgSwDI mice at 3 months-of-age during the Porsolt swim test (Figure 
3.6E) represents increased depressiveness in the animals or is an artifact of their 
reduced locomotion. 
49 
Figure 3.7. TgSwDI mice exhibit reduced mobility. During behavioral testing for 
cognitive decline, TgSwDI mice demonstrated reduced mobility in the Y-maze (A) 
and Barnes maze (B) tests compared to age-matched WT controls. Mobility was 
reduced in this mouse line at both 3 and 6 months-of-age using both tests (A,B; 
*p<0.05, **p<0.01, ***p<0.001). At 2 months-of-age, TgSwDI mice only exhibited
reduced locomotion during Y-maze testing. Given that increased latency to 
immobility was observed at 3 months-of-age during the Porsolt swim test, it is 
possible that the Porsolt swim test result is suggestive of motor differences, rather 
than a depressive-like phenotype in TgSwDI mice. 
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TgSwDI Background Characterization 
Since the TgSwDI mouse model was generated on a pure C57Bl6J background50, 
C57Bl6J mice were initially used as controls. This method was beneficial, since 
frequent genotyping and separation of mice were not required during breeding. 
Additionally, TgSwDI mice were used as homozygotes and two copies of the 
transgene resulted in earlier and more severe pathology and both TgSwDI and 
C57Bl6J mice could be ordered to supplement experiments if breeding was slow. 
However, after establishing that the behavior of this colony of TgSwDI mice was 
inconsistent with published reports52 (Figures 3.1, 3.6, 3.7), DNA samples from two 
of eight colony founder mice were sent for background characterization to determine 
if C57Bl6J was the correct control based on the background of the TgSwDI mice 
from this colony.  
An initial 384 SNP background strain characterization test (Charles River) indicated 
that both founder animals were mostly C57Bl6J (99.73% and 99.61%).  However, 
both animals were found to be heterozygous for a marker on chromosome 10 in a 
region polymorphic between C57Bl6J and C57Bl6N substrains, indicating that the 
TgSwDI mice from this colony had a mixed C57Bl6 background. 
Though C57Bl6 substrains arose from the same mouse line, decades of breeding in 
separate facilities have resulted in subtle genomic divergence63. Two spontaneous 
mutations have arisen in coding sequence DNA since the two lines have been bred 
separately. The Crb1 gene contains a 1bp deletion in C57Bl6N mice compared to 
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C57Bl6J and a deletion in the Nnt gene can now be found in C57Bl6J mice. Though 
these differences are seemingly inconsequential, other groups have reported 
behavioral differences between C57Bl6J and N substrains64. Further analysis on 
colony founder DNA involved the examination of 15 microsatellite markers showing 
polymorphism between C57Bl6 substrains (Charles River). Microsatellite marker 
testing showed that both founder mice had slightly more C57Bl6J in their genetic 
backgrounds than C57Bl6N (62.5% and 65.62%). The unique differences between 
the founders at these microsatellite sites are listed in Table 3.1. The importance of 
the D2Mit277, D6Mit116, D11Mit71, and D18Mit49 loci, which were different in the 
two founders, are not known, as these regions have not been studied in detail. The 
Nnt gene, which was polymorphic between the two founders, encodes a 
mitochondrial NAD(P) transhydrogenase. This integral inner mitochondrial 
membrane protein couples hydride transfer between NAD(H) and NADP(+) to proton 
translocation across the inner mitochondrial membrane. The importance of this 
polymorphism is unclear, since the effect of each polymorphism on gene product 
production and function is not known. 
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Table 3.1. Mixed background of TgSwDI mice. 
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Use of Homozygotes vs. Heterozygotes 
Due to the mixed background observed in the colony of TgSwDI mice being studied 
and the potential effects of strain background on behavioral characteristics in mice, 
TgSwDI mice were crossed with C57Bl6J mice to generate TgSwDI +/- and -/- for 
future use. Though the background would still be mixed for these mice, the 
background would be similarly mixed in the littermates used as controls.  
Importantly, preliminary studies conducted on this mouse line (Figures 3.1-3.7) 
employed TgSwDI homozygotes. The new breeding and genotyping scheme would 
require the use of heterozygotes. The onset and severity of pathology is likely to 
vary between homozygotes and heterozygotes and previously published reports on 
this mouse line describe experiments done with homozygotes. Thus findings in 
heterozygotes are likely to be less severe at any given time point due to expression 
of one copy of transgenic APP rather than two. 
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CHAPTER 4: INDUCING HYPERTENSION IN TGSWDI MICE 
Assessment of Methods for Inducing Hypertension in Mice 
Surgical, genetic and chemical techniques have been developed to induce 
hypertension in rodent models for research. Surgical models entail the ligation of the 
renal artery or abdominal aorta, or removal of one kidney. All of these techniques 
result in reduced kidney function. Since the kidneys regulate the amount of fluid in 
the body as well as arterial constriction and damaged kidneys often overproduce 
renin, these techniques increase arterial constriction and result in high BP. The 
transverse aortic constriction (TAC) model has also been used for studying the 
effects of hypertension on the brain and heart65. TAC, which involves ligation of the 
transverse aorta, causes increased BP and blood volume in the vasculature leading 
up to the point of constriction, which includes the right carotid artery as well as the 
heart.  
Ultimately, surgical techniques for inducing hypertension were avoided, because 
wounds resulting from surgical techniques are susceptible to infection or injury. 
Wounded mice often require single-housing so that they are protected from fighting 
with other mice as well as easily monitored while they heal. Social isolation in mice 
in turn results in altered behavior in a number of behavior tests and has even been 
shown to exacerbate AD pathology66-68. Thus, surgically-induced hypertension was 
likely to result in experimental artifacts based on housing conditions and/or a smaller 
experimental cohort.  
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Genetic models of hypertension involve overexpression of WT or transgenic renin, 
resulting in increased circulating Ang-II. Ang-II stimulates vascular smooth muscle 
cells and results in their contraction69. Ang-II also stimulates ion exchange in the 
kidneys resulting in increased blood volume, BP and blood pH70. In fact, Ang-II is so 
effective at increasing BP that angiotensin converting enzyme (ACE), the enzyme 
required for production of Ang-II, is the target of a major group of antihypertensive 
drugs, the ACE inhibitors71. Angiotensin receptor blockers (ARBs) or Sartans, 
another group of commonly used antihypertensive drugs, are effective due to their 
action in preventing Ang-II binding to receptors72. Genetic models to induce 
hypertension were not ideal, since AD mouse models can be weak when crossed to 
other strains. Often the mixture of the genetic background is important to the survival 
of a strain when a deleterious transgene, such as mutated APP, is inserted into the 
genome. Changing the background of a strain can result in changes in litter size, 
pup survival and birth rates. Also, generating a double-transgenic mouse colony 
often requires many months to achieve cohorts large enough for experimentation, 
even when adjusting the genetic background of the strain has no impact on 
reproduction and survival of the mice.  
Finally, chemical models of hypertension involve administration of chemical 
components of the pathway that regulates BP endogenously and/or chemicals that 
regulate the production of pathway components. Direct Ang-II administration is one 
example of this. Ang-II treatment can be paired with administration of L-NAME to 
provide a two-pronged approach to increasing BP73. Chemical models are useful 
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since treatment can be adjusted to yield more or less severe hypertension. 
Treatments are also often easy to administer or withhold from mice at different time 
points, depending on experimental requirements, which is not true for surgical or 
genetic models. 
Ang-II and L-NAME-Induced Hypertension in AD Mouse Models  
Ang-II is a component of the endogenous renin-angiotensin system, which controls 
BP in mammals. The serum globulin angiotensinogen is produced in the liver and 
released into the circulation, where it becomes activated by renin to form angiotensin 
I. Angiotensin I is converted to Ang-II by ACE. Ang-II is a potent vasoactive peptide 
and, because it causes vasoconstriction, it can independently raise BP when 
delivered subcutaneously. 
L-NAME supplementation of Ang-II treatment has been described as a useful 
technique for inducing hypertensive intracerebral hemorrhage (ICH) in rodents73. L-
NAME is an endothelial cell nitric oxide synthase (eNOS) inhibitor. Nitric oxide 
synthases (NOS) catalyze the production of nitric oxide (NO) from L-arginine 
endogenously. NO is an important cellular signaling molecule and also modulates 
vascular tone, insulin secretion, peristalsis, angiogenesis and neural development74. 
It also functions in the brain as a retrograde neurotransmitter75. Three forms of NOS 
are produced endogenously: eNOS, which is produced by endothelial cells; nNOS, 
which is produced by neurons; and iNOS, or inducible NOS, which increases levels 
of NO as an immune defense against pathogens. L-NAME causes vasoconstriction 
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by selective inhibition of eNOS, which is produced by the vascular endothelium to 
induce vasodilation. Therefore, L-NAME directly inhibits the ability of the 
endothelium to dilate and relieve spikes in BP caused by physiological changes, 
such as increased levels of Ang-II.  
Ang-II infusion along with L-NAME administration were used in early attempts to 
increase BP in 3 different mouse models of AD used in the lab: TgSwDI, Tg6799 
and TgCRND8. However, Ang-II and L-NAME administration together resulted in 
seizures and increased mortality shortly after initiation of treatment in all three 
mouse lines (Figure 4.1A).  Additionally, the use of this model for induction of ICH by 
other groups was worrisome73, since this would be a potential limitation on treatment 
duration. For this reason, no further experiments were conducted using this 
technique. 
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Figure 4.1. Effect of treatments to induce hypertension on long-term survival 
in AD mouse lines. L-NAME and Ang-II were used to induce hypertension in the 
TgSwDI, Tg6799 and TgCRND8 AD mouse lines. After the start of treatment (Day 
0), mortality increased in all three mouse lines (A). TgCRND8 mice exhibited the 
most extreme drop in survival during treatment, followed by TgSwDI and Tg6799 
mice. Frequent seizures were observed in L-NAME and Ang-II-treated mice of each 
strain. No increase in mortality was observed in untreated mice. (B) Given this drop 
in survival following combined L-NAME and Ang-II treatment, TgSwDI and WT mice 
were treated with L-NAME alone. Both groups exhibited an increase in BP from 
baseline levels (Day -2) without any associated increase in mortality (not shown) 




Due to the increased mortality observed in AD mice following Ang-II and L-NAME 
administration (Figure 4.1A), L-NAME treatment alone was examined for its effects 
on BP (Figure 4.1B). Administration of L-NAME increased BP in both TgSwDI and 
WT mice (Figure 4.1B). BP rose gradually after initiation of treatment (Day 0) and 
remained elevated after the first 3-4 weeks of treatment. Additionally, treatment of 
mice for up to 5 months resulted in no increase in mortality in either genotype (not 
shown).  
One benefit of this method relative to other treatment types was that the amount of 
L-NAME administered could be adjusted easily since L-NAME was delivered in the 
drinking water of the mice. Additionally, no surgical incisions were required for L-
NAME administration. Even if AD mice could tolerate Ang-II treatment alone for an 
extended duration, Ang-II was infused through a subcutaneous pump that required a 
small incision on the back of each mouse for insertion. Additionally, the infusion 
pump used for Ang-II delivery required replacement once contents were expelled 
every 2-4 weeks. Thus, the duration of treatment would have been limited by the 
cost of the pumps and the number of times animals could be anesthetized and 
operated on before suffering extensive surgical trauma. Since long-term L-NAME 
administration could best mimic chronic human hypertension, which can last 
decades, it was selected as the method for inducing hypertension in TgSwDI mice.  
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CHAPTER 5: EFFECTS OF HYPERTENSION ON ALZHEIMER’S 
NEUROPATHOLOGY IN TGSWDI MICE 
Cognitive Decline 
L-NAME was used to chemically induce hypertension in TgSwDI and WT mice 
(Figure 5.1). This protocol was designed to mimic the pattern of hypertension that 
predisposes humans to LOAD, which occurs in individuals with midlife hypertension 
prior to indications of cognitive decline34, 76, 77. Since TgSwDI mice are predisposed 
to AD, hypertension was induced at 3-4 months-of-age, which corresponds to early 
adulthood in humans, but is before AD-related cognitive decline was observed in this 
mouse line (Figure 3.1). Mice were treated for 3 or 6 months and were 6-7 or 9-10 
months during testing and analysis, respectively. L-NAME-treated WT and TgSwDI 
mice exhibited a significant increase in BP compared to water-treated animals, 
which stabilized after the first four weeks of treatment (Figure 5.2A). There were no 
differences in levels of CD31 or α-smooth muscle actin between normotensive and 
hypertensive groups throughout treatment (not shown), suggesting that hypertension 
did not affect the overall number of vessels in brain tissue in these animals. The 
Barnes maze was used to compare the cognitive abilities of normotensive and 
hypertensive WT and TgSwDI mice. After 3 months of L-NAME treatment, TgSwDI 
mice performed significantly worse during the 5-day probe trial compared to water-
treated TgSwDI mice and all WT mice (Figure 5.2B), indicating that chronic 
hypertension impacted cognition after only 3 months, well before significant cognitive 
impairment was evident from the transgene alone. Following 6 months of treatment, 
hypertensive TgSwDI mice performed worse during Barnes maze training, taking 
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significantly longer to find the escape hole compared to all other groups (Figure 
5.2C). Unlike the homozygote cohort (Figure 3.7), there were no differences in 
baseline locomotor activity between any of the groups when heterozygotes and 
littermate controls were tested (not shown). Interestingly, this cohort of water-treated 
TgSwDI mice (9-10 months-of-age) did not have cognitive deficits relative to WT 
mice in this test, though chronic hypertension was able to induce significant 
cognitive dysfunction.  
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Figure 5.1. L-NAME-induced chronic hypertension experimental setup. IVF was 
used to generate a cohort of TgSwDI +/- mice from TgSwDI +/+ and C57Bl6J mice. 
The males from this cross and age-matched C57Bl6J males were used to test the 
experimental paradigm (pilot group). When they reached 3-4 months-of-age, half of 
the mice of each genotype were treated with L-NAME (hypertensive) for 3 or 6 
months, at which time they were sacrificed. The rest of the cohort was treated with 
water. At 8 weeks of age, the female TgSwDI +/- mice generated from the first cross 
were subsequently crossed with C57Bl6J male mice using IVF to generate a new 
cohort of TgSwDI +/- and -/- mice (experimental group). Because they were 
generated by IVF, all members of the experimental cohort were age-matched and 
the controls were littermates. Mice of each genotype were treated with either L-
NAME or water as described for the pilot group. After 3 or 6 months, behavioral 
experiments were conducted and mice were sacrificed for tissue analysis. 
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Figure 5.2. Chronic L-NAME treatment induces hypertension in WT and 
TgSwDI mice and accelerates AD-related cognitive decline. (A) WT and TgSwDI 
mice administered L-NAME in their drinking water exhibited significantly elevated BP 
compared to water-treated groups (***p<0.001 for effect of treatment for each 
genotype). Mice treated with water maintained constant BP. Treatments started on 
day 0, after baseline BP was measured. (B) TgSwDI mice treated with L-NAME for 3 
months exhibited cognitive deficits in the Barnes maze relative to untreated TgSwDI 
and WT groups. During the probe trial carried out 5 days after training, hypertensive 
TgSwDI mice approached the target hole less frequently than normotensive TgSwDI 
(*p<0.05) and WT (p<0.05) mice. There was no effect of hypertension on cognitive 
function in WT mice. (C) Long-term hypertension, induced by L-NAME treatment for 
6 months, affected learning in TgSwDI mice, which exhibited extended latencies to 
find the target hole during training compared to normotensive TgSwDI mice 
(***p<0.001), an effect not observed after 3 months of L-NAME treatment [not 
shown; n=8-12/group (A), 10-12/group (B,C)].  
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Vascular Amyloid Deposition 
To determine if increased levels of Aβ in the hippocampus were responsible for the 
cognitive deficits observed in hypertensive TgSwDI mice, ThioS was used to detect 
fibrillar Aβ. Sections were co-stained with an anti-collagen IV antibody, which 
recognizes the basement membrane of capillaries. After quantifying the total length 
of capillaries stained by collagen IV in the DS of each mouse, the length of vessels 
in the same sections that was stained by ThioS was quantified. These values were 
used to calculate the percent of DS capillaries with CAA. Aβ in the DS of 
normotensive TgSwDI mice was microvascular and parenchymal (Figure 5.3A, D). 
However, there were fewer plaques observed in hypertensive TgSwDI mice and 
significantly more CAA (Figure 5.3B, E). These results demonstrated that this 
microvascular Aβ staining was increased in hypertensive mice compared to 
normotensive animals (Figure 5.3C, F), yet there was not an increase in overall Aβ 
levels (not shown), suggesting that hypertension increased the likelihood that Aβ 
would be deposited microvascularly. The small number of plaques observed in 
hypertensive TgSwDI mice (Figure 5.3E) could have been the result of new Aβ 
production and/or deposition, since plaque-like deposits of Aβ were observed in 
earlier stages of disease before microvascular Aβ deposits were observed (Figure 
3.2). Immunoelectron microscopy (IEM) analysis confirmed that the Aβ deposited in 
these mice was microvascular. Bundles of electron-dense finger-like clusters 
adhered to the basement membrane surrounding microvessels and stained positive 
with a pan-amyloid marker (Figure 5.3G). 
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Figure 5.3. Hypertensive TgSwDI mice exhibit increased microvascular Aβ 
deposition. ThioS (green) and an anti-collagen IV antibody (red) were used to 
determine levels of CAA in normotensive (A,D) and hypertensive (B,E) TgSwDI 
mice. CAA levels were significantly increased after 3 (B,C) and 6 (E,F) months of L-
NAME treatment (***p<0.001 or **p<0.01 normotensive TgSwDI vs. normotensive 
WT; ***p<0.001 or *p<0.05 normotensive vs. hypertensive TgSwDI; scale bar=50 
µm; n=7-8/group). (G) Microvascular Aβ deposition, observed by immunoelectron 
microscopy, appeared as dark finger-like projections adhering to the basement 
membrane of capillaries in hypertensive TgSwDI brains (L, lumen; E, endothelial 
cell; scale bar=500 nm).  
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Microgliosis 
Since activated astrocytes and microglia are often abundant in tissue with Aβ 
deposition78, glial markers were examined in normotensive and hypertensive 
TgSwDI and WT brains (Figure 5.4). Though levels of astrocyte markers were 
similar in normotensive and hypertensive TgSwDI mice (not shown), the microglial 
marker Iba-1 was upregulated in hippocampal subregions of hypertensive TgSwDI 
mice compared to those of normotensive mice (Figure 5.4 B,E vs. A,D). Iba-1 
expression was significantly higher in water-treated TgSwDI mice compared to 
water-treated WT mice and was even higher in L-NAME-treated TgSwDI mice 
(Figure 5.4C,F). The pattern of Iba-1 staining in the DG appeared patchy (Figure 
5.4B), likely due to the presence of larger parenchymal plaques in this region, 
compared to the DS, where the staining appeared vascular (Figure 5.4E). Due to the 
vascular appearance of Iba-1 in the DS, electron microscopy (EM) was used to 
examine Aβ-laden microvessels and confirm that CAA was often surrounded by 
infiltrating microglia (M in Figure 5.4G). 
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Figure 5.4. Hypertensive TgSwDI mice display increased vascular 
microgliosis. Microgliosis was examined in tissues using an anti-Iba-1 antibody 
(green) and vessels were stained with an endothelial cell-specific anti-CD31 
antibody (red). Compared to water-treated TgSwDI (A,D) and WT (not shown) 
groups, the DG (B) and DS (E) of hypertensive TgSwDI brains exhibited significantly 
more Iba-1 staining after 6 months of treatment (C,F; **p<0.01 normotensive 
TgSwDI vs. normotensive WT; *p<0.05 or ***p<0.001 normotensive vs. hypertensive 
TgSwDI; scale bar=100 µm; n=6-9/group). (G) The infiltration of microglia was 
observed by EM of brain capillaries in hypertensive TgSwDI samples. Capillaries 
laden with Aβ (*) were surrounded by infiltrating microglial nuclei (M, microglia; L, 
lumen; scale bar=2 µm).  
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BBB Integrity  
Since the BBB is disrupted in AD patients and mouse models79-81, BBB integrity was 
examined to determine if hypertension affected this feature of AD pathology. Under 
normal conditions, tight junctions, which form the basis of the BBB82, appear 
continuous and lay flat, preventing diffusion of blood components into the brain83 
(Figure 1.2, 5.5A). However, the tight junctions in samples from hypertensive 
TgSwDI mice appeared to be breaking off into the capillary lumen and lifting slightly 
from the endothelial cell layer (arrowheads in Figure 5.5B-D), providing an 
opportunity for BBB leakage. Given these structural alterations, tissue was examined 
for the presence of blood components that could enter the brain if BBB integrity were 
compromised. Albumin was elevated in the DS and DG of hypertensive TgSwDI 
brains when compared to normotensive TgSwDI brains after only 3 months of 
treatment, indicating that BBB integrity was compromised due to hypertension 
(Figure 5.5G,H). 
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Figure 5.5. Hypertensive TgSwDI mice have increased BBB disruption. 
Compared to capillary structure in water-treated mouse vessels (A), capillaries in 
brains of hypertensive TgSwDI mice exhibited tight junction alterations (arrowheads 
in B-D). Compared to the structure of normal tight junctions (arrow in A), those of 
hypertensive TgSwDI mice were often lifting or fragmented (arrowheads in B-D). The 
plasma protein albumin, which was present at low levels in the DS of normotensive 
TgSwDI brains (E), was significantly enriched in the DS (F-H; *p<0.05) and DG (not 
shown) of hypertensive TgSwDI mice after 3 months of L-NAME treatment. 
Compared to normotensive WT mice, hypertensive WT mice also exhibited 
significant leakage of albumin from the vasculature into the DS after 3 months of L-




Though no changes were observed in levels of astrocyte markers examined in the 
experimental cohort (not shown) and despite similarities in microglial markers 
between the pilot and experimental cohorts (Figure 5.4, 5.6A,B), initial analysis of 
the pilot cohort revealed dramatic changes in astrocytic markers. Levels of glial 
fibrillary acidic protein (GFAP) were significantly increased in the hippocampi of 
hypertensive TgSwDI mice (Figure 5.6C,D).  
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Figure 5.6. Hypertensive TgSwDI mice from the pilot group exhibit increased 
microgliosis and astrocyte activation. The elevation in Iba-1 levels in the DS of 
hypertensive TgSwDI mice in the experimental group was also seen in hypertensive 
TgSwDI mice in the pilot group when examined using an anti-Iba-1 antibody (A, 
brown; B, ***p<0.001 normotensive TgSwDI vs. normotensive WT, **p<0.01 
normotensive vs. hypertensive TgSwDI). However, the astrocyte marker GFAP, 
which was not differentially regulated in hypertensive TgSwDI mice compared to 
normotensive animals in the experimental group (not shown), was significantly 
increased in hypertensive TgSwDI mice (C) compared to normotensive mice (not 
shown) in the pilot group, as well as in hypertensive WT mice compared to 
normotensive control mice (D; **p<0.01 normotensive vs. hypertensive WT, 
***p<0.001 normotensive TgSwDI vs. normotensive WT, *p<0.05 normotensive vs. 
hypertensive TgSwDI). GFAP (red) was observed as dense staining in the DG and 
DS (not shown) of hypertensive TgSwDI mice from the pilot group (C, scale bar = 
100 µm).  
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Additionally, levels of the water channel protein aquaporin-4 (AQP-4) appeared 
dramatically misregulated in hypertensive TgSwDI from the pilot group (Figure 5.7). 
Overall staining intensity was significantly increased in hypertensive TgSwDI mice 
(Figure 5.7D,J) relative to normotensive TgSwDI mice (Figure 5.7C,I), as well as 
nomortensive (A,G) and hypertensive WT mice (B,E,H,K).  Despite this increase, 
localization of the endfoot marker along capillaries was largely absent (Figure 
5.7F,L). These changes were subtle in normotensive TgSwDI, but severe in 
hypertensive TgSwDI mice. Importantly, hypertensive WT mice exhibited increased 
AQP-4 staining intensity as well as vessel coverage (Figure 5.7E,F,K,L), suggesting 
that the hypertension-induced alterations that occurred in WTs were misregulated in 
TgSwDI mice.  Levels of α-syntrophin, an anchoring protein for AQP-4, were also 
reduced in the pilot cohort (not shown). Reduction in levels of this protein could 
contribute to AQP-4 mislocalization.  
77 
Figure 5.7. Hypertensive TgSwDI mice from the pilot group display 
mislocalized protein expression in astrocyte endfeet. The astrocyte endfoot 
marker AQP-4 was identified using an anti-AQP-4 antibody (red) in tissue from both 
the pilot and experimental cohorts. Despite seeing no differences in AQP-4 staining 
in mice from the experimental group (not shown), AQP-4 levels were increased in 
both the DG (A-D) and DS (G-J) of hypertensive TgSwDI mice (D, J) compared to 
normotensive TgSwDI mice (C, I) after 3 and 6 months of treatment. AQP-4 staining 
in normotensive (A,G) and hypertensive (B,H) WT animals showed what appeared 
to be vascular staining, consistent with the adherence of endfeet to capillaries. In 
hypertensive TgSwDI mice, staining was no longer localized to capillaries (F,L) and 
was dramatically upregulated (E,K), a pattern also observed in normotensive 
TgSwDI mice, but to a less dramatic extent. Notably, L-NAME treatment increased 
both AQP-4 staining intensity and vessel coverage in WTs, suggesting that the effect 
of hypertension on AQP-4 levels is misregulated in TgSwDI mice (*p<0.05, **p<0.01, 




Pericyte loss occurs in severely affected AD patients84 and in older TgSwDI mice28, 
so levels of PDGFRβ were quantified to determine if the expression of this pericyte 
marker was altered in hypertensive groups. After 6 months of L-NAME treatment, 
hypertensive TgSwDI mice exhibited a significant decrease in PDGFRβ staining in 
both the DG and DS (Figure 5.8 A,D vs. B,E). Taken together, these results suggest 
that pericyte loss can occur at a much earlier age when there is concomitant 
hypertension.  
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Figure 5.8. Hypertensive TgSwDI mice exhibit early pericyte loss. Anti-PDGFRβ 
antibody was used to examine pericyte coverage of vessels in normotensive (A,D) 
and hypertensive (B,E) TgSwDI mice. (C,F) PDGFRβ levels were significantly 
reduced in hypertensive TgSwDI mice in the DG and DS compared to control groups 
after 6 months of treatment (*p<0.05, **p<0.01; scale bar=50 µm; n=5-9/group). 
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Neuronal Loss 
Neurodegeneration is a hallmark feature of AD, but many mouse models of this 
disease do not exhibit this pathology83. Under normal conditions, the TgSwDI mouse 
model also does not show signs of neuronal loss85. However, due to the accelerated 
timecourse of other pathologies in L-NAME-treated TgSwDI mice, the hippocampus 
was examined and exhibited significantly reduced neuronal staining in the DS 
(Figure 5.9). This degeneration occurred after short-term L-NAME treatment (3 
months) and at only 6-7 months-of-age, when no neuronal loss was evident in 
normotensive TgSwDI mice (Figure 5.9 A-C). Normotensive TgSwDI mice at 9-10 
months-of-age began to exhibit signs of neuronal loss (Figure 5.9D), making 
hypertension-induced cell death at this age less dramatic (Figure 5.9F). 
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Figure 5.9. Hypertensive TgSwDI mice exhibit early neuronal loss. Anti-NeuN 
antibody was used to identify neurons in the DS of normotensive (A,D) and 
hypertensive (B,E) TgSwDI mice. (C) Reduced NeuN intensity was observed in 
hypertensive TgSwDI mice after 3 months of L-NAME treatment (*p<0.05, n=3-
9/group). (F) Since NeuN intensity was slightly decreased in normotensive TgSwDI 
animals after 6 months of treatment due to advanced age (9-10 months-of-age), 
there was no longer a significant difference between groups. Although NeuN 
intensity appeared reduced in the DS of hypertensive WT mice compared to 
normotensive WT mice after 3 and 6 months of treatment, neither change was 
significant (C,F; *p<0.05; scale bar=50 µm; n=5-9/group).  
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Although the pericyte loss observed in hypertensive TgSwDI mice (Figure 5.8) has 
been reported in 18 month-old TgSwDI homozygote mice without hypertension28, 
neuronal loss has never been reported in this mouse model at any age. This is an 
important finding, since neuronal loss is a widely accepted hallmark of AD, yet does 
not occur in many commonly used AD models86. 
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CHAPTER 6: EFFECTS OF HYPERTENSION ON AUTOPHAGY IN TGSWDI MICE 
Increased Autophagy in Hypertensive TgSwDI Mice at the NVU 
Autophagy was first identified using EM techniques87 and EM is still used to identify 
autophagic compartments morphologically	  46. EM has superior resolution compared 
to light microscopy and many antibodies used to identify autophagic compartments 
by immunofluorescence or light microscopy are unsuccessful. By EM, lysosomes 
appear as uniformly electron-dense intracellular spheres87. Endosomes and MVBs, 
which have been reported to carry Aβ into cells for degradation in AD88, appear as 
round bodies containing smaller spheres of various electron densities89.  
Early ultrastructural observations of hypertensive TgSwDI brain tissue revealed 
abundant autophagic activity. Lysosomes and MVBs were often present near sites of 
CAA in hypertensive TgSwDI brain tissue processed for EM (Figure 6.1) and have 
been observed in all cellular components of the NVU, including microglia, pericytes, 
astrocytic endfeet and endothelial cells, within a narrow block of tissue at one time 
(not shown). This is unusual, since it is rare to see lysosomal activity in healthy brain 
tissue due to the rapid rate of autophagic flux42. Both microglia and astrocytes are 
known to take up and degrade Aβ deposited in AD8, 90. However, the participation of 
pericytes, endothelial cells and the endfeet of astrocytes in clearance of CAA has 
not been reported.   
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Figure 6.1. Lysosomes are present in multiple NVU cell types in hypertensive 
TgSwDI mice. (A-D) EM images showed the presence of lysosomes, which 
appeared as electron-dense spheres, in multiple cell types in hypertensive TgSwDI  
brain tissue. (A) Microglia nuclei (*) were present at the basement membrane of a 
capillary, likely due to the presence of Aβ nearby (not shown). The dark spheres 
within the microglia shared morphological characteristics with lysosomes 
(arrowhead), while the nearby round bodies containing spheres of different electron 
densities were morphologically similar to MVBs. Lysosomes and/or MVBs were also 
abundant in pericytes (B), astrocyte endfeet (C) and endothelial cells (D) in 
hypertensive TgSwDI mice (L, lumen; scale bar = 2 µm in A, 1 µm in B,C,D).  
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Lysosomal Protein Expression is Increased in Hypertensive TgSwDI Mice 
Given the increased abundance of lysosomes observed in NVU cell types in 
hypertensive TgSwDI brains, levels of autophagic markers were examined in brain 
sections from these animals (Figure 6.2). LAMP-1 was used as a marker as 
previously described for the characterization of neuropathology in TgSwDI 
homozygous mice (Figure 3.5). Levels of LAMP-1 were significantly increased in 
hypertensive TgSwDI mice (Figure 6.2A,B). The staining pattern of LAMP-1 in the 
DS resembled that of microglia in the same mice (Figure 5.4E), consistent with the 
observation of lysosomes in microglia (Figure 6.1) as well as in other NVU cell types. 
Cathepsin D (CATD), a lysosomal aspartyl protease involved in degradation of 
proteins within lysosomes	  91, was also increased in hypertensive TgSwDI mice 
(Figure 6.2 C,D) and showed a similar staining pattern to that of Iba-1 and LAMP-1 
(Figure 5.4E, 6.2A).  Microglial co-staining is required to confirm cell type-specific 
expression of these markers.  
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Figure 6.2. Levels of lysosomal markers are increased in hypertensive  
TgSwDI mice. Given the abundance of lysosomes observed by EM at the NVU in 
hypertensive TgSwDI mouse brains, tissue sections from hypertensive TgSwDI mice 
were examined for the presence of lysosomal markers. Levels of LAMP-1, a protein 
found on endosomal and lysosomal membranes, were increased in the DS of both 
normotensive (not shown) and hypertensive TgSwDI (A) groups relative to WT 
groups (B, ***p<0.001). Moreover, levels of LAMP-1 were significantly increased in 
hypertensive TgSwDI mice relative to normotensive TgSwDI mice (B, **p<0.01). 
Since LAMP-1 is not specific for lysosomes, levels of the lysosomal protease CATD 
were examined using an anti-CATD antibody. Again, both normotensive (not shown) 
and hypertensive TgSwDI (C) groups exhibited a significant increase in CATD levels 
relative to WT mice (D, **p<0.01). Elevated levels of CATD were also observed in 
hypertensive TgSwDI mice relative to normotensive TgSwDI mice (D, ***p<0.001), 
similar to what was observed with LAMP-1 staining (scale bar = 50 µm).  
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Effect of Hypertension on Astrocyte Endfoot Morphology 
By EM, astrocyte endfeet appeared less electron-dense than surrounding cells 
(Figure 1.2). In normotensive WT mouse brains, lysosomes as well as vacuolar 
structures within astrocyte endfeet were occasionally observed (not shown).  
However, such vacuoles were abundant in astrocyte endfeet in both hypertensive 
WT (Figure 6.3A) and hypertensive TgSwDI mice (Figure 6.3B).  
These vacuoles were morphologically similar to structures observed in primary 
cortical neuron cultures from rat pups after induction of autophagy by rapamycin 
treatment42. These structures are also morphologically similar to known autophagic 
structures: MVBs, AVs and multilamellar bodies (MLBs) (Figure 6.4). Thus, it is 
possible that the vacuolar structures observed in the endfeet of hypertensive 
TgSwDI and WT mouse brains were produced during autophagic flux. However, 
since the identity of these structures has not yet been confirmed by IEM analysis or 
by examination after induction or suppression of autophagy, they will be referred to 
as autophagic compartments (ACs) herein. In hypertensive TgSwDI and WT brain 
tissue, ACs are so abundant that they appear to cause dramatic swelling of the 
astrocyte endfeet (Figure 6.3).  
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Figure 6.3. Hypertension causes buildup of ACs in swollen astrocyte endfeet. 
The buildup of ACs is most noticeable in the astrocyte endfeet of hypertensive WT 
(A) and TgSwDI (B) mouse brains. Astrocyte endfeet are typically more electron-
dense than surrounding tissue (Figure 1.2). In hypertensive TgSwDI and WT mice, 
the accumulation of ACs resulted in a dramatic enlargement of these astrocytic 
processes. In (A), two MLBs (arrow) are observed amongst the ACs while in (B), a 
lysosome (arrowhead) can be observed (L, lumen; scale bar = 2 µm).  
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Figure 6.4. ACs in hypertensive mice share morphological features with 
autophagic structures. ACs observed using EM in hypertensive WT (A) and 
TgSwDI (B,C) mice resemble different autophagic structures. The round 
compartments and darker components contained within the membrane of the AC 
shown in A resemble features of an MVB. The structure in B is morphologically 
similar to an AV, which has membranes surrounding less electron-dense 
components. An AC that shared characteristics of an MLB can be observed in C. 
Due to their morphological similarities to a variety of different autophagic structures, 
ACs may refer to multiple entities, rather than one discrete type of autophagic body 
(scale bars = 500 nm). 
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Clearance of ACs Through the BBB 
Further EM analysis revealed that ACs were often localized within tight junctions of 
endothelial cells in hypertensive TgSwDI and WT mice (Figure 6.5).  The localization 
of ACs to tight junction structures may have altered the permeability of the BBB and 
contributed to the BBB leakage observed in hypertensive TgSwDI and WT mice 
(Figure 5.5).  
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Figure 6.5. ACs are cleared through the BBB in hypertensive mice. ACs are 
often abundant within tight junction structures in hypertensive WT (A,B) and TgSwDI 
(C,D) mice, but never in normotensive WT or TgSwDI mice (not shown). Moderate 
(A,C) to severe (B,D) disruption of the tight junctions can be observed in the brains 
of hypertensive mice of both genotypes (scale bar = 500 nm). The disruption of tight 
junctions in hypertensive mice due to the presence of ACs may contribute to the 
reduced BBB integrity observed in these animals.  
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The frequent presence of ACs within the lumen of capillaries in hypertensive mice 
(Figure 6.6) suggests active clearance of these structures from the brain to the 
blood. Clearance of ACs could have occurred through endothelial tight junctions 
(Figure 6.5) or through exocytosis by endothelial cells (Figure 6.7). Clearance of 
autophagic structures into the blood has not been reported previously, so should be 
considered with caution. However, potentially similar mechanisms, such as receptor-
mediated transcytosis, have been reported92. 
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Figure 6.6. Hypertension causes buildup of ACs in the capillary lumen. 
Lumenal ACs were observed in brain capillaries of hypertensive TgSwDI (A,B) and 
WT (C) mice. ACs were observed in the lumen of capillaries at low (A), moderate (B) 
and high (C) abundance in hypertensive mice of both genotypes. The presence of 
ACs in the capillary lumen suggests that ACs were being cleared from the brain into 
the circulation (scale bars = 500 nm). 
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It is likely that the ACs observed in the lumen of capillaries by EM (Figure 6.6) were 
in the process of being exocytosed by endothelial cells, since completely detached 
structures would have been carried away by capillary flow or perfusion. Three-
dimension electron microscopy (3D-EM) revealed that ACs that appeared to be 
detached in the lumen were actually attached to endothelial cells at nearby points 
not captured in the EM image (Figure 6.7). 
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Figure 6.7. ACs are exocytosed from endothelial cells in hypertensive mice. 
Sequential EM images processed using 3View are presented in order of image 
collection from left-to-right and top-to-bottom. Early during image capture, the AC 
(red box) observed in the capillary lumen of a hypertensive TgSwDI mouse, 
appeared completely lumenal. Images captured at different points along the Z-axis 
(presented here at 100-nm intervals) show that the AC was attached to the nearby 
endothelial cell. The endothelial cell appeared to be in the process of exocytosing 
the AC into the capillary lumen (scale bar = 1 µm).  
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Though ACs were occasionally observed in astrocyte endfeet in normotensive WT 
mice, they were very rarely observed within the lumen of capillaries in normotensive 
TgSwDI or normotensive WT mice (not shown). Notably, they were never observed 
within tight junction structures in normotensive animals. For this reason, the ACs that 
appeared to disrupt the BBB seem to be a product of hypertension.  
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CHAPTER 7: DISCUSSION AND CONCLUSIONS 
Pathological Timecourse in TgSwDI Mice 
The hippocampus coordinates memory consolidation and spatial navigation and is 
one of the first regions in the brain to suffer damage in AD93. The DG receives all 
hippocampal inputs and passes them through the hippocampus proper (CA1-4) to 
the subiculum, which projects out of the hippocampus to the entorhinal cortex94. 
Thus, proper function of the DG, which receives all hippocampal inputs, and the 
subiculum, which sends hippocampal projections, are essential to memory 
consolidation and spatial navigation. Additionally, rat studies suggest that the 
subiculum is involved in the spread of Aβ, as lesions in this region inhibit plaque 
formation in other brain regions95. The earliest pathological changes observed in the 
TgSwDI mouse model occurred in the subiculum (Figure 3.2-3.5).  It is unclear why 
this occurs, since expression of the APP transgene is not localized to particular brain 
regions in the TgSwDI mouse line. The cognitive deficits observed in TgSwDI mice 
as well as the pathological progression observed throughout the brain over time may 
be due in large part to the presence of early pathology in the subiculum. 
Given the abundance of Aβ plaques in brains of humans with severe AD, it is 
unclear whether Aβ deposits are a contributor to dysfunction in the disease or 
merely an indication of pathological severity. Interestingly, at 2 months-of-age, 
TgSwDI mice exhibited dramatic microglia activation in the DS (Figure 3.3D) relative 
to the amyloid deposited at this age, which was undetectable (Figure 3.2A). Since 
the transgenic mutations in TgSwDI mice result in overproduction of Aβ, it is 
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reasonable to assume that Aβ production is the cause of the early microglial 
activation, since no activation was observed in WT mice at any age (Figure 3.3). 
Importantly, though no fibrillar Aβ deposits were detected in TgSwDI mice at 2 
months-of-age by ThioS staining, soluble forms of Aβ may still have been present 
and may have resulted in the observed activation of microglia. LAMP-1 staining was 
also increased in TgSwDI mice at around 3 months-of-age, again prior to 
widespread plaque or CAA pathology. The timecourse of these changes suggests 
that microglial activity at 2 months-of-age was able to keep Aβ deposition low, but 
was overwhelmed at around 3 months-of-age when Aβ deposition was first observed 
in these mice (Figure 3.2B). At this age, observable increases in autophagy were 
also noted (Figure 3.5B). Alternatively, early soluble forms of Aβ could have 
fibrillized after reaching a certain threshold. It is unclear whether changes in 
expression of autophagy markers represent dysfunctional autophagy or simply 
upregulated autophagy serving to control the increasing Aβ load in the brain. It is 
also unclear whether fibrillar and oligomeric forms of Aβ had different effects on the 
microglia activation or autophagic processes observed96, 97. It is possible that early 
mechanisms acting to clear plaques observed at 3 months-of-age resulted in 
microvascular deposition of Aβ by 6 months-of-age, as well as a reduction in plaque 
size and number. It is also possible that early plaques were easily cleared, while 
amyloid deposited as CAA occurred later during the pathological timecourse, but 
persisted.  
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Breakdown of the BBB was observed as early as 3 months-of-age in TgSwDI 
homozygotes. Since Aβ deposition was not severe and was also not vascular at 3 
months-of-age (Figure 3.2B), the early increases in microgliosis and autophagy may 
be more directly linked to loss of BBB integrity than Aβ abundance or CAA. If 
opening of the BBB were in fact a mechanism for removal of Aβ from the brain, as 
proposed in Chapter 6 (Figure 6.5, 6.7), the timescale of increased BBB permeability 
is consistent with the timescale of other clearance mechanisms relative to Aβ load. 
However, the basis for such a hypothesis is not well established and requires 
confirmation. 
Accelerated Neuropathology in Hypertensive TgSwDI Mice 
Under normal conditions, hypertension induces pathological changes within the 
cerebral vasculature, resulting in impaired autoregulation, microbleeds, and lacunar 
infarcts, as well global downstream changes, such as WMLs and atrophy31, 98-103. In 
fact, these changes within the cerebral vasculature of hypertensive individuals also 
occur in AD patients in the absence of hypertension104-106. Additionally, midlife 
hypertension is a significant risk factor for the development of AD later in life16. 
Hypertension may initiate vascular damage prior to the onset of AD, allowing 
symptoms to be more pronounced and progress more quickly after onset. 
Additionally, compromised vessels may be more vulnerable to the deleterious effects 
of Aβ. For example, since hypertension results in reduced BBB integrity (Figure 5.5), 
blood components may enter the brain before large-scale accumulation of Aβ 
occurs. These blood components may serve as a seed for Aβ deposition and 
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increase vascular inflammation (Figure 5.4), resulting in cellular damage and the 
release of toxic molecules107.  
The location, but not abundance, of Aβ deposits was altered in hypertensive TgSwDI 
mice, which also exhibited dramatic cognitive decline. These findings suggest that 
microvascular Aβ contributed more to cognitive decline than parenchymal plaques. 
CAA deposits were found to adhere to capillary basement membranes (Figure 
5.3G), which normally bind NVU cells together. For this reason, Aβ deposited as 
CAA may act as a physical barrier to cell signaling at the NVU. Moreover, CAA could 
obstruct astrocyte endfoot binding and contribute to pericyte loss (Figure 5.8). Both 
astrocytes and pericytes are involved in the recruitment of blood flow during 
neuronal activity and damage to or interference with signaling of these cell types in 
hypertensive TgSwDI mice may impair neurovascular coupling. 
Aβ is thought to be deposited as CAA due to failed clearance across the BBB and 
along perivascular spaces108. Since L-NAME treatment resulted in increased CAA in 
TgSwDI mice without an overall increase in Aβ levels, hypertension may have a 
detrimental effect on these Aβ clearance pathways. L-NAME inhibits eNOS and 
thereby prevents the production of the vasodilator NO. It could be that NO-mediated 
vasodilation is required for effective clearance of Aβ across the BBB or along 
perivascular drainage pathways. If L-NAME disrupted this process, Aβ would be 
preferentially deposited along capillaries, as observed in hypertensive TgSwDI mice. 
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The neuronal loss in hypertensive TgSwDI mice (Figure 5.9) could have resulted 
from the proposed reductions in blood flow as well as impaired function of NVU 
support cells that either degenerate (pericytes; Figure 5.8) or are chronically 
activated (microglia; Figure 5.4). Since brain atrophy is associated with hypertension 
in humans 31 and hypertensive WT mice exhibited a trend towards reduced neuron 
number, it is possible that the vascular changes that occur during hypertension in 
WT mice, such as BBB leakage (Figure 5.5), affect neuronal health. However, the 
changes specific to TgSwDI mice with hypertension, such as dramatically increased 
microgliosis (Figure 5.4) and severe CAA (Figure 5.3) likely contributed in some 
way. In addition to the cytotoxic effects of Aβ itself109-111, activated microglia are 
known to produce cytotoxic molecules107, which may damage neurons.  Therefore, 
the increased microvascular Aβ deposition and microgliosis in hypertensive TgSwDI 
mice, but not in hypertensive WT mice, may have contributed to the neuronal loss 
observed in this group. 
Though models of comorbid hypertension and AD are limited, the results presented 
here are consistent with what has been observed in other models. Ang-II infusion in 
APPPS1 mice results in a more rapid onset of AD pathology112. It is possible that 
long-term hypertension facilitated by the use of L-NAME exacerbated previously 
observed pathologies, such as cognitive decline (Figure 5.2) and early and dramatic 
Aβ deposition (Figure 5.3), and revealed new neuropathologies not previously 
observed, such as microglia activation (Figure 5.4), BBB leakage (Figure 5.5), and 
pericytic and neuronal loss (Figure 5.8, 5.9). 
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Studies linking hypertension with AD define midlife as the time between the ages of 
40 and 64 years. Midlife hypertension is associated with an increased risk of 
developing AD, but hypertension later in life (≥65 years-of-age) does not have this 
association. Given that heterozygous TgSwDI mice developed AD symptoms around 
6 months-of-age (Aβ deposition, microgliosis; Figures 5.3, 5.4) and cognitive decline 
around 10-12 months (not shown), hypertension was induced at a time point 
corresponding to early adulthood developmentally, to maximize the duration of 
hypertension before the onset of AD symptoms. Importantly, studies linking 
hypertension with AD examine BP prior to onset of AD symptoms. Though midlife 
hypertension is a significant risk factor for AD and treatment alleviates this risk34, 36, 
dramatic reduction in BP often occurs at later stages of AD, after which point 
antihypertensive use is deleterious to cognitive function33, 34. Hypertension may 
compromise vascular integrity during midlife and lead to cellular, basement 
membrane and/or BBB damage. However, after the onset of AD symptoms, low BP 
may aggravate brain hypoperfusion already present in AD due to other types of 
vascular damage. Additionally, since patients exhibit low BP during moderate and 
severe AD stages, rather than during mild cognitive impairment, and since the 
association between low BP and AD becomes stronger in more severe cases of AD, 
it has been proposed that AD somehow causes the low BP observed in patients35. 
This may be due to loss of or damage to cell types that control blood flow or it could 
be a result of other changes that often occur over the course of the disease, such as 
weight loss and reduced activity.  
107 
Although others have shown pericyte loss in TgSwDI mice at 18 months-of-age28, L-
NAME-induced chronic hypertension caused pericyte loss significantly earlier (9-10 
months-of-age; Figure 5.8). Furthermore, neuronal loss has never been reported in 
this transgenic model, yet hypertensive TgSwDI mice demonstrated significant 
neurodegeneration in a subregion of the hippocampus (Figure 5.9). Moreover, not 
only did hypertension result in quantifiable neuronal loss, but it did so quite early (6-7 
months-of-age) relative to the few other mouse lines that exhibit this feature of 
AD113. At 6-7 months-of-age, the first indications of AD (Aβ deposition, 
neuroinflammation, cognitive decline) are often just becoming apparent in other AD 
mouse models113-115. These findings are notable, since neuronal loss is widely 
accepted as a hallmark of AD, yet does not occur in many commonly used AD 
models86. If hypertension indeed accelerates AD pathogenesis, then a reasonable 
hypothesis is that neuronal loss is a downstream effect of the abundant 
microvascular amyloid pathology observed in TgSwDI mice. Neuronal loss is often 
not reported in AD mice possibly due to their short lifespans relative to the time 
required for AD to result in neuronal loss in humans. Pairing hypertension with 
genetic predisposition to AD may represent a more complete model of AD than 
traditional AD mouse models.  
The Effects of Hypertension on Autophagy in TgSwDI and WT Mice 
Abnormalities of the lysosomal system have been identified in the AD brain, though 
these findings have only been described in neurons116. Given that CAA is increased 
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in hypertensive TgSwDI mice (Figure 5.3) without increased overall levels of Aβ or 
an altered ratio of Aβ40 to 42 compared to normotensive TgSwDI mice (not shown) 
and that lysosomal markers LAMP-1 and CATD are also increased in hypertensive 
TgSwDI mice, it is possible that Aβ deposited microvascularly differentially affects 
autophagic processes relative to Aβ deposited as plaques in the brain. This process 
could be due to the cell types located near CAA and the ability of these cell types to 
take up and degrade Aβ (Figure 1.2). Although CAA seems to increase autophagic 
flux in NVU cell types, the most dramatic changes in autophagic processing appear 
to be brought about by hypertension.   
Typically when identification of autophagic structures is based on morphology alone, 
only vesicles containing cytoplasmic material, in most cases ribosomes or 
mitochondria, can be called autophagic in mammalian cells117. Given the lack of 
electron-dense material inside ACs, the supposition that they may be remnants of an 
autophagic process is purely speculative. 
Normal AV induction, but impaired clearance would theoretically result in an 
abundance of membrane-bound compartments with little electron-dense material 
inside116. The ACs observed in hypertensive brains are most similar in appearance 
to AVs, a term which has been used to refer to autophagosomes, amphisomes and 
autolysosomes. Thus, AV is a general term for autophagy-related vesicular 
structures at an intermediate stage in autophagic flux 116. AVs are less electron-
dense than MVBs and have fewer surrounding membranes than MLBs (Figure 6.4). 
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However, since structures resembling AVs, MVBs and MLBs have been observed in 
the brains of hypertensive mice, it is possible that “AC”, as it is used here, refers to a 
group of structures at different points in autophagic processing. 
In general, the ratio of early to late autophagic compartments is indicative of the 
cause of accumulation117. ACs in hypertensive animals appear to be at a late stage 
of clearance due to their lack of electron-dense components, since even late 
autophagic compartments typically still contain electron-dense material117. 
Accumulation of late autophagic compartments, may suggest a defect in ultimate 
degradation of these structures. 
Autophagy is induced in heart tissue during hypertensive heart disease118 as well as 
in neurons in the brains in hypertensive animals119. Hypertension is also known to 
increase levels of Aβ in WT mice due to RAGE-mediated Aβ-influx through 
endothelial cells37. Since ACs were rarely observed in normotensive TgSwDI mice, 
despite their high Aβ load relative to hypertensive WT mice, it is possible that the 
mechanism by which Aβ enters the brain is involved in production of ACs. 
Importantly, APP is present in membranes of organelles involved in autophagy47 and 
Aβ production may be elevated during the increased autophagic flux that occurs 
during hypertension. Hypertension could also alter autophagic processes at the NVU 
by causing damage to the cell types responsible for Aβ clearance. If cells are 
prevented from properly degrading Aβ, this could result in the observed buildup of 
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ACs in hypertensive TgSwDI and WT brains (Figure 6.3, 6.5, 6.6), as well as the 
increased CAA in hypertensive TgSwDI mice (Figure 5.3).  
Since ACs were observed in the lumen of capillaries in normotensive WT mice, 
albeit rarely, clearance of ACs through endothelial cell exocytosis may be a transient 
mechanism for the transfer of brain components to the blood. This process may play 
a role in cellular waste removal from the brain, supplementing clearance along 
perivascular drainage pathways108. This process could turn over rapidly in 
normotensive WT mice, but could be altered in hypertensive animals leading to 
buildup of ACs near endothelial cells. 
Whether the proposed opening of the BBB for clearance of ACs would result in 
improved removal of cellular waste components from the brain or a dramatic 
infiltration of blood components into the brain and subsequent neuroinflammation is 
unclear. Deleterious changes involving increased BBB permeability, such as 
microhemorrhage and increased risk of stroke, have been observed in AD12, 13. 
However, some recent studies have shown that focused ultrasound (FUS) is 
effective in clearing Aβ from the brain and restoring cognitive abilities in rodent 
models of AD120, due to activation of glia and transient and focal opening of the BBB 
to endogenous antibodies. Importantly, neither the increased BBB permeability in 
TgSwDI mice due to hypertension (Figure 5.5) nor the increase in microglial 
activation (Figure 5.4) appears to have a positive effect on cognitive function (Figure 
5.2) or Aβ-load (Figure 5.3). Perhaps the presence of increased levels of Aβ within 
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the microvasculature impacts the infiltration of useful endogenous antibodies into the 
brain in TgSwDI mice. Importantly, FUS appeared to have an effect on the activation 
state of microglia, as they increase in size, though not in number, after FUS. The 
increased Iba-1 staining in hypertensive TgSwDI mice does not necessarily reflect a 
microglial state of increased Aβ clearance. Additionally, FUS localizes BBB 
permeability to specific areas rather than increasing general BBB permeability, 
which could have different effects on Aβ clearance.  
In tissue from hypertensive TgSwDI mice with CAA, endfeet appeared to be 
enlarged due to abundance of ACs that collected there (Figure 6.3).  Swollen 
astrocyte endfeet have been observed in a variety of conditions from schizophrenia 
to ischemia, as well as in CAA21, 22, 121, 122. However, since ACs are poorly defined 
currently, the similarity of swollen astrocyte endfeet in hypertensive TgSwDI mice 
compared to swollen endfeet observed in other conditions is unclear. Since 
astrocyte endfeet perform quite a large number of neuronal support functions at the 
NVU123-125, disruption of their morphology and function could have dramatic effects 
on neuronal health and function. Given the close physical relationship between 
astrocyte endfeet and CAA, as well as the increased presence of ACs within 
endfeet, it is very surprising that the experimental cohort did not show disruption in 
astrocytic markers (not shown). Since ACs are occasionally observed in astrocyte 
endfeet in normotensive WT tissue, though never within tight junction structures (not 
shown), it is unclear whether they are part of a normal process that occurs 
transiently in WT brains or whether they are indicative of pathology. It is possible 
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that the endfeet are a common site for autophagic processes given the well-
described role of astrocytes in degradation and protein clearance9. However, this 
process may be disrupted due to hypertension and thus ACs appear much more 
frequently near hypertensive capillaries in the brain. 
Future Directions 
Most of the changes observed in the hypertensive TgSwDI mice from the 
experimental cohort were also observed in the pilot cohort (not shown). However, 
differences in astrocyte markers in the hypertensive TgSwDI group in the pilot cohort 
(Figures 5.6, 5.7) were not recapitulated in the experimental cohort. One difference 
between these two cohorts that could account for this difference is that the pilot 
cohort contained only male mice. This was due to the fact that the females were 
undergoing a second round of IVF in order to generate mice for the experimental 
cohort. The presence of estrogen in the brains of female mice may be slightly 
neuroprotective126. If repeated analysis reveals that important astrocyte markers are 
normal in hypertensive TgSwDI brains from the experimental cohort, repeating the 
experiment using only male mice may be useful in order to investigate additional 
features of astrocyte pathology.  
It would be interesting to examine levels of tight junction proteins in hypertensive 
and normotensive brains of each genotype to determine if markers of tight junctions 
are altered. Reduced expression of tight junction markers may contribute to the 
fragmentation of tight junctions observed by EM in hypertensive TgSwDI mice 
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(Figure 5.5) and the disrupted tight junction structures in hypertensive TgSwDI and 
WT mice due to the presence of ACs and the BBB leakage observed in these 
animals (Figure 5.5). 
Previous attempts to confirm that the ACs were indeed autophagic by IEM were 
unsuccessful, because techniques required for ultrastructural preservation can 
interfere with antigenicity. This work is ongoing with different antibodies that might 
display stronger binding to tissue fixed for EM. It would also be useful to know if the 
ACs contain soluble Aβ, such as the more toxic oligomeric forms of the protein127. I 
would expect this to be the case if transcytosis of ACs were a mechanism for 
removal of Aβ from the brain, rather than simply evidence of dysfunctional lysosomal 
clearance mechanisms. The fact that levels of Aβ oligomers in plasma negatively 
correlate with AD severity in patients, suggests that clearance through the blood 
may reflect a mechanism for preserving cognitive ability and when it is disrupted, 
cognitive function suffers128.  
Though EM is very useful for the qualitative study of cellular phenomena, 
quantification of findings by EM can be more challenging than by traditional light or 
fluorescence microscopy. Measurement of the ratio of early to late autophagic 
compartments by Western blotting may provide insight into the disruption that occurs 
in hypertensive mice. Unfortunately, less is known about molecular markers involved 
in clearance of autophagic structures than formation and maturation42. Comparison 
of hypertensive and normotensive WT mice may also provide information regarding 
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the nature of ACs, since autophagic flux appears to occur normally in normotensive 
WT mice. To what extent ACs build up in astrocytes and tight junctions in 
hypertensive WT compared to hypertensive TgSwDI mice also remains to be 
determined. Finally, examination of human tissue with and without hypertension and 
with and without comorbid AD will be important to confirm that the findings described 
are relevant to humans with these conditions and not an artifact of L-NAME 
treatment itself.  
APOE is involved in cellular uptake of Aβ as well as trafficking of Aβ to lysosomes in 
an isoform-dependent manner129. Interestingly, there is a stronger correlation for 
protective effect of antihypertensive drug use among APOE4 carriers130, 131. 
Antihypertensive drug use appears to abolish the risk of LOAD conferred by the 
APOE4 allele. This correlation could be explained by a common effect of APOE4 
and hypertension on autophagy. If both risk factors disrupted autophagic processes, 
then their coincidence would exacerbate the effect of one or the other alone. 
Examining brain tissue from APOE4 individuals with and without hypertension could 
shed light on the interaction between these two risk factors. 
Understanding the molecular pathways responsible for buildup of ACs as well as the 
proposed exocytosis through endothelial cells could potentially prove therapeutically 
useful. If AC exocytosis through endothelial cells were a mechanism for removal of 
cellular waste, enhancing this process may prove beneficial, especially in the case of 
hypertension, where the process appears to occur inefficiently.  If this process 
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instead results in loss of BBB integrity and leakage of blood components into the 
brain, inhibiting it might prove more therapeutically beneficial. 
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